[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 135
1. Suehiro K, Pritzwald-Stegmann P, Lee KM, Teoh HH, Alison PM: Mediastinal and pulmonary metastases of malignant ossifying fibromyxoid tumor. Ann Thorac Surg; 2006 Jun;81(6):2289-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal and pulmonary metastases of malignant ossifying fibromyxoid tumor.
  • Ossifying fibromyxoid tumor is usually a benign tumor.
  • However some of these tumors with histologic and clinical evidence of malignancy have also been reported and little information is available regarding surgery for metastatic ossifying fibromyxoid tumor.
  • We present a case involving extensive excision of a huge metastatic ossifying fibromyxoid tumor occupying the upper mediastinum and upper half of the right hemithorax.
  • [MeSH-major] Fibroma, Ossifying / pathology. Lung Neoplasms / secondary. Mediastinal Neoplasms / secondary
  • [MeSH-minor] Adult. Brain Neoplasms / complications. Brain Neoplasms / secondary. Diagnostic Errors. Fatal Outcome. Female. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Humans. Lipoma / diagnosis. Neoplasm Invasiveness. Pericardium / pathology. Pericardium / surgery. Phrenic Nerve / pathology. Phrenic Nerve / surgery. Pneumonectomy. Radiotherapy, Adjuvant. Reoperation. Seizures / etiology. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Superior Vena Cava Syndrome / etiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731174.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


2. Tamura K, Aoyagi M, Wakimoto H, Tamaki M, Yamamoto K, Yamamoto M, Ohno K: Malignant transformation eight years after removal of a benign epidermoid cyst: a case report. J Neurooncol; 2006 Aug;79(1):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation eight years after removal of a benign epidermoid cyst: a case report.
  • Malignant transformation of benign epidermoid cysts is rare and their prognosis remains poor.
  • She had undergone removal of a benign epidermoid cyst in the cerebellopontine angle 8 years previously.
  • Magnetic resonance imaging of the brain revealed a cystic lesion in the left cerebellopontine angle.
  • She underwent removal again and the histopathologic diagnosis was squamous cell carcinoma.
  • The tumor shrank rapidly for 2 months after radiosurgery, but recurred 9 months later.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic / pathology. Cerebellar Neoplasms / pathology. Cerebellopontine Angle / pathology. Epidermal Cyst / pathology
  • [MeSH-minor] Female. Gadolinium. Humans. Image Enhancement. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Radiosurgery

  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 1995 Jul-Aug;19(4):628-30 [7622698.001]
  • [Cites] No Shinkei Geka. 1987 Aug;15(8):851-8 [3323934.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1237-43 [12450053.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Nov-Dec;12(6):1182-4 [1763747.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):538-41 [6886769.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1984;402(4):459-64 [6202051.001]
  • [Cites] J Neurosurg. 1965 Oct;23(4):384-93 [5853888.001]
  • [Cites] Neurol Med Chir (Tokyo). 1999 Jan;39(1):49-54 [10093462.001]
  • [Cites] Cancer. 1973 Mar;31(3):713-8 [4693599.001]
  • [Cites] Acta Neurochir (Wien). 1987;85(1-2):34-9 [3604769.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Jun;43(6):275-80; discussion 281 [12870545.001]
  • [Cites] J Clin Neurosci. 2001 Nov;8(6):572-4 [11683611.001]
  • [Cites] Cancer. 2005 May 15;103(10):2143-53 [15816051.001]
  • [Cites] J Neurosurg. 1979 Jun;50(6):830-3 [312314.001]
  • [Cites] AJNR Am J Neuroradiol. 1989 Mar-Apr;10(2):351-6 [2494855.001]
  • [Cites] J Neurosurg. 1964 Dec;21:1051-8 [14279825.001]
  • [Cites] Neurosurgery. 1989 Apr;24(4):574-8 [2651960.001]
  • [Cites] No Shinkei Geka. 1990 Nov;18(11):1041-5 [2247198.001]
  • [Cites] J Neurosurg. 1981 Oct;55(4):654-6 [7277016.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1965 Jun;28:276-81 [14345685.001]
  • [Cites] J Neurosurg. 1987 Apr;66(4):618-20 [3559730.001]
  • [Cites] Neurol Med Chir (Tokyo). 1989 Jul;29(7):600-5 [2477760.001]
  • [Cites] N Engl J Med. 1977 Feb 3;296(5):271-6 [299778.001]
  • [Cites] J Comput Assist Tomogr. 1981 Jun;5(3):433-5 [6972395.001]
  • [Cites] Br J Neurosurg. 1993;7(5):565-9 [8267896.001]
  • [Cites] Br J Neurosurg. 1991;5(3):303-5 [1892574.001]
  • [Cites] Neurosurgery. 1995 Aug;37(2):329-32 [7477788.001]
  • [Cites] No Shinkei Geka. 1995 Oct;23(10):905-9 [7477700.001]
  • [Cites] Curr Opin Oncol. 1997 May;9(3):262-6 [9229149.001]
  • (PMID = 16583265.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


3. Schaller BJ, Modo M, Buchfelder M: Molecular imaging of brain tumors: a bridge between clinical and molecular medicine? Mol Imaging Biol; 2007 Mar-Apr;9(2):60-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?
  • As the research on cellular changes has shed invaluable light on the pathophysiology and biochemistry of brain tumors, clinical and experimental use of molecular imaging methods is expanding and allows quantitative assessment.
  • Molecular imaging sets forth to probe the molecular abnormalities that are the basis of disease rather than to visualize the end effects of these molecular alterations and, therefore, provides different additional biochemical or molecular information about primary brain tumors compared to histological methods "classical" neuroradiological diagnostic studies.
  • Common clinical indications for molecular imaging contain primary brain tumor diagnosis and identification of the metabolically most active brain tumor reactions (differentiation of viable tumor tissue from necrosis), prediction of treatment response by measurement of tumor perfusion, or ischemia.
  • The interesting key question remains not only whether the magnitude of biochemical alterations demonstrated by molecular imaging reveals prognostic value with respect to survival, but also whether it identifies early disease and differentiates benign from malignant lesions.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neurons / diagnostic imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Animals. Cell- and Tissue-Based Therapy. Disease Models, Animal. Disease Progression. Humans. Molecular Probes. Neoplasm Staging. Radiography

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2003 Jun;111(11):1620-9 [12782662.001]
  • [Cites] Nucl Med Commun. 2003 Nov;24(11):1149-54 [14569169.001]
  • [Cites] Acta Radiol. 1989 Mar-Apr;30(2):121-8 [2493795.001]
  • [Cites] J Nucl Med. 1993 Jan;34(1):12-7 [8418251.001]
  • [Cites] Ann Neurol. 2003 Oct;54(4):479-87 [14520660.001]
  • [Cites] Expert Opin Biol Ther. 2004 Feb;4(2):145-55 [14998774.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Neurol Med Chir (Tokyo). 1998 Jun;38(6):342-7; discussion 347-8 [9689817.001]
  • [Cites] Mol Imaging. 2002 Oct;1(4):309-35 [12926228.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8122-5 [14678964.001]
  • [Cites] J Comput Assist Tomogr. 1993 Sep-Oct;17 (5):681-7 [8370819.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1018-25 [15877226.001]
  • [Cites] Nucl Med Biol. 2004 Feb;31(2):179-89 [15013483.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):623-9 [16036113.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):653-9 [15711980.001]
  • [Cites] Expert Rev Neurother. 2006 May;6(5):723-30 [16734520.001]
  • [Cites] Neuroradiology. 1998 Feb;40(2):103-8 [9541920.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1862-7 [11912166.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1376-86 [12216107.001]
  • [Cites] J Neurooncol. 2004 May;68(1):1-9 [15174514.001]
  • [Cites] Acta Neurol Scand. 2005 Feb;111(2):75-83 [15644065.001]
  • [Cites] J Nucl Med. 1991 Apr;32(4):726-8 [2013813.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]
  • [Cites] Bone Marrow Transplant. 2002 Jul;30(2):103-11 [12132049.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):414-6 [15770001.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Nov;31(11):1530-8 [15378285.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1255-62 [14977823.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):417-24 [10667596.001]
  • [Cites] Blood. 2003 Jul 1;102(1):53-9 [12609836.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7571-4 [14633668.001]
  • [Cites] Hum Gene Ther. 2003 Feb 10;14(3):277-97 [12639307.001]
  • [Cites] Radiology. 2001 May;219(2):316-33 [11323453.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):491-5 [11228541.001]
  • [Cites] J Neurooncol. 1992 Feb;12 (2):159-65 [1560262.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Dev Neurosci. 2004 Mar-Aug;26(2-4):118-30 [15711055.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12846-51 [11070094.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(1):1-15 [10664370.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Acta Radiol Suppl. 1986;369:157-60 [2980438.001]
  • [Cites] J Neurochem. 1977 May;28(5):897-916 [864466.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):498-507 [16235683.001]
  • [Cites] J Comput Assist Tomogr. 1992 Jan-Feb;16(1):62-8 [1729308.001]
  • [Cites] Chest. 2003 Aug;124(2):608-13 [12907550.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Neurosurgery. 1994 Jun;34(6):994-1002; discussion 1002 [8084410.001]
  • [Cites] J Biol Chem. 1999 Jul 9;274(28):19745-51 [10391916.001]
  • [Cites] Neurology. 1982 Dec;32(12 ):1323-9 [6983044.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5657-63 [12384520.001]
  • [Cites] Lancet. 2001 Sep 1;358(9283):727-9 [11551583.001]
  • [Cites] NeuroRx. 2005 Apr;2(2):333-47 [15897954.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):64-74 [16111573.001]
  • [Cites] Radiology. 1995 Oct;197(1):221-6 [7568827.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jan;61(1):58-63 [11829344.001]
  • [Cites] Acta Otolaryngol. 1997 Jul;117(4):482-9 [9288200.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jul-Aug;17 (4):509-61 [8392523.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):393-403 [16513607.001]
  • [Cites] J Nucl Med. 2005 Mar;46(3):450-4 [15750158.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8 [14595012.001]
  • [Cites] NMR Biomed. 2003 Apr;16(2):67-76 [12730947.001]
  • [Cites] Eur J Nucl Med. 2001 Dec;28(12 ):1851-72 [11734927.001]
  • [Cites] Invest Radiol. 1987 May;22(5):360-71 [3496318.001]
  • [Cites] Mol Imaging Biol. 2004 Jul-Aug;6(4):239-69 [15262239.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):207-15 [15332323.001]
  • [Cites] Neurosurg Rev. 1999 Dec;22(4):210-4 [10682929.001]
  • [Cites] Mol Imaging Biol. 2004 May-Jun;6(3):139-48 [15193248.001]
  • [Cites] Eur J Nucl Med. 1997 Sep;24(9):1149-55 [9283109.001]
  • [Cites] Magn Reson Med. 2004 May;51(5):893-9 [15122670.001]
  • [Cites] J Nucl Med. 2001 Mar;42(3):467-75 [11337525.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):427-36 [8057151.001]
  • [Cites] J Nucl Med. 2000 Apr;41(4):661-81 [10768568.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1781-5 [11280722.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6101-8 [15342393.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):789-803; discussion 803-4 [9092853.001]
  • [Cites] J Nucl Med. 2003 Dec;44(12 ):1962-9 [14660722.001]
  • [Cites] Nat Biotechnol. 2003 Apr;21(4):405-13 [12652311.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9300-5 [11481488.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):157-63 [11206011.001]
  • [Cites] Q J Nucl Med. 1995 Sep;39(3):243-9 [7552947.001]
  • [Cites] J Nucl Med. 2005 Dec;46(12 ):1948-58 [16330557.001]
  • [Cites] J Neurosurg. 1999 Nov;91(5):797-803 [10541237.001]
  • [Cites] Eur J Nucl Med. 1997 Apr;24(4):428-34 [9096095.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 4:139-43 [12401680.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2572-9 [15059914.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1459-62 [9293808.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):231-6 [10563428.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):505-11; discussion 505-11 [16145529.001]
  • [Cites] Mol Ther. 2004 Nov;10(5):916-28 [15509509.001]
  • [Cites] Leukemia. 2002 Feb;16(2):260-7 [11840293.001]
  • [Cites] Int J Cancer. 2001 Jun 20;96(3):191-7 [11410888.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 May;31(5):740-51 [15014901.001]
  • [Cites] J Cereb Blood Flow Metab. 1984 Jun;4(2):212-23 [6609929.001]
  • [Cites] Blood. 2005 Jan 1;105(1):420-5 [15331444.001]
  • [Cites] J Comput Assist Tomogr. 1983 Dec;7(6):1062-6 [6415134.001]
  • [Cites] J Neuroimaging. 2003 Jul;13(3):269-71 [12889176.001]
  • [Cites] J Nucl Med. 1994 Jul;35(7):1162-6 [8014676.001]
  • [Cites] Nat Med. 2000 Apr;6(4):447-50 [10742153.001]
  • [Cites] Neurosurgery. 1993 Jul;33(1):28-33 [8355844.001]
  • [Cites] J Cereb Blood Flow Metab. 1991 May;11(3):485-91 [2016357.001]
  • [Cites] AJR Am J Roentgenol. 1988 Jan;150(1):189-97 [3257119.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73 [12692687.001]
  • [Cites] J Magn Reson Imaging. 2004 Apr;19(4):389-96 [15065161.001]
  • [Cites] Exp Cell Res. 2005 Jun 10;306(2):323-9 [15925587.001]
  • [Cites] Radiology. 1993 Jan;186(1):45-53 [8380108.001]
  • [Cites] J Nucl Med. 1999 Mar;40(3):381-6 [10086699.001]
  • [Cites] Neurosurgery. 1989 Nov;25(5):720-8 [2586726.001]
  • [Cites] Nat Med. 2004 Nov;10(11):1257-60 [15502845.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5347-54 [15289341.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):43-52 [10924970.001]
  • [Cites] J Nucl Med. 1991 Jul;32(7):1338-46 [1906093.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1369-74 [9293789.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2983-95 [11306477.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):227-37 [14558598.001]
  • [Cites] Trends Neurosci. 2005 Mar;28(3):120-6 [15749164.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):265-72 [11134222.001]
  • [Cites] Clin Nucl Med. 1996 Sep;21(9):720-5 [8879874.001]
  • [Cites] J Nucl Med. 1998 May;39(5):778-85 [9591574.001]
  • [Cites] J Neurosurg. 2003 May;98 (5):1056-64 [12744366.001]
  • [Cites] Nervenarzt. 2003 Dec;74(12):1134-6 [14647916.001]
  • [Cites] Neurobiol Dis. 2004 Apr;15(3):437-48 [15056451.001]
  • [Cites] Radiographics. 1992 Mar;12 (2):269-79 [1561416.001]
  • [Cites] Stereotact Funct Neurosurg. 1997;69(1-4 Pt 2):129-35 [9711745.001]
  • [Cites] Eur J Nucl Med. 1996 May;23 (5):583-6 [8698067.001]
  • [Cites] Pediatr Neurosurg. 1997 Mar;26(3):144-56 [9419031.001]
  • [Cites] J Nucl Med. 2004 Nov;45(11):1939-45 [15534066.001]
  • [Cites] Cancer. 1994 Nov 15;74(10):2836-42 [7954245.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1074-8 [3261622.001]
  • [Cites] J Neurosurg. 1985 Jun;62(6):816-22 [2987440.001]
  • (PMID = 17203238.001).
  • [ISSN] 1536-1632
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Molecular Probes
  • [Number-of-references] 135
  •  go-up   go-down


Advertisement
4. Andrychowski J, Taraszewska A, Czernicki Z, Jurkiewicz J, Netczuk T, Dabrowski P: Ten years observation and treatment of multifocal pilocytic astrocytoma. Folia Neuropathol; 2009;47(4):362-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is a benign, generally well-delineated, WHO grade I tumour with favorable prognosis, which makes it different from diffuse astrocytomas, classified as higher grades of malignancy.
  • A case study of PA was presented in a young female patient, observed and treated at the Neurosurgical Department for the period of 10 years, during which time she had frequent surgical procedures due to recurrence and dissemination of the tumour.
  • Neuroradiological study revealed cerebral tumour in the right temporal lobe, then the first temporal lobe surgery followed by re-operation and radiotherapy was performed.
  • After 5 years local recurrence of the tumour appeared in the right temporal region.
  • The patient was operated and the tumour was totally removed.
  • Initially, the histopathological diagnosis of ganglioglioma was suggested for primary tumour, finally the diagnosis of pilocytic astrocytoma for both recurrent and primary tumour was established.
  • The spinal tumour was surgically treated in both locations; the last operation was done 10 years after surgery of the primary temporal lobe tumour.
  • Histopathological examinations of the excised foci from spinal canal revealed neoplasm consistent with WHO grade I pilocytic astrocytoma.
  • The presented case indicates that despite the spread of the neoplastic process, a histopathologically benign tumour (WHO I grade) allows for long-term survival and observation period.
  • Unfortunately, multifocal tumour involving midline structures causes major neurological symptoms and deficits.

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20054789.001).
  • [ISSN] 1509-572X
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


5. Plans G, Brell M, Cabiol J, Villà S, Torres A, Acebes JJ: Intracranial retrograde dissemination in filum terminale myxopapillary ependymomas. Acta Neurochir (Wien); 2006 Mar;148(3):343-6; discussion 346
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myxopapillary ependymomas (ME) are considered benign tumours (WHO grade I) of the central nervous system with long term survival rates and a tendency to local recurrence.
  • We describe the case of a 23-year-old man diagnosed with intracranial subarachnoid dissemination of a filum terminale ME three years after the initial diagnosis.
  • [MeSH-major] Brain Neoplasms / secondary. Cauda Equina / pathology. Ependymoma / secondary. Meningeal Neoplasms / secondary. Neoplasm Metastasis / physiopathology. Spinal Cord Neoplasms / pathology. Subarachnoid Space / physiopathology
  • [MeSH-minor] Adult. Decompression, Surgical. Disease Progression. Headache / diagnosis. Headache / etiology. Headache / physiopathology. Humans. Hypothalamic Neoplasms / radiotherapy. Hypothalamic Neoplasms / secondary. Hypothalamus / pathology. Hypothalamus / physiopathology. Hypothalamus / surgery. Laminectomy. Low Back Pain / etiology. Low Back Pain / physiopathology. Low Back Pain / surgery. Lumbar Vertebrae / surgery. Magnetic Resonance Imaging. Male. Pituitary Gland, Posterior / pathology. Pituitary Gland, Posterior / physiopathology. Pituitary Gland, Posterior / surgery. Radiotherapy / methods. Third Ventricle / pathology. Third Ventricle / physiopathology. Third Ventricle / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16362177.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 35
  •  go-up   go-down


6. Campos WK, Linhares MN: Sporadic intramedullary spinal cord hemangioblastoma in a newborn. Pediatr Neurosurg; 2010;46(5):385-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hemangioblastomas (HB) are rare lesions accounting for 2% of all spinal cord tumors.
  • They are highly vascular, benign tumors that occur either sporadically or in the presence of von Hippel-Lindau disease.
  • MRI of the spine revealed an intramedullary tumor extending from level T6 to T12.
  • RESULTS: The tumor was excised completely, using standard microsurgical techniques via a posterior approach.
  • The histological diagnosis was spinal cord HB.
  • CONCLUSION: A review of the literature revealed that this neoplasm is composed of 3 major cell types: endothelial cells, pericytes and stromal cells.
  • Complete microsurgical removal is the treatment of choice for spinal cord HB because the tumor is benign.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Hemangioblastoma / surgery. Spinal Cord Neoplasms / surgery

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21389752.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


7. Shimizu J, Matsumoto M, Yamazaki E, Yasue M: Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo); 2008 May;48(5):227-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain computed tomography incidentally revealed a left frontal lobe tumor measuring 5 cm in a diameter.
  • The patient had a history of taking chlormadinone acetate (a progesterone agonist) prescribed several years previously as treatment for benign prostatic hypertrophy.
  • The tumor was seen as an isointense lesion on T(1)-weighted magnetic resonance (MR) images with enhancement by gadolinium, and as a heterogeneously hyperintense mass on T(2)-weighted MR images.
  • The tentative diagnosis was left frontal meningioma attached to the sphenoid ridge or sphenoid plane.
  • The medication for benign prostatic hypertrophy was changed from chlormadinone acetate to naftopidil (an alpha-2-blocker) about 9 months after his first presentation.
  • Computed tomography and MR imaging performed at this time revealed remarkable regression of the tumor.
  • The signal intensity change with regression of the tumor on T(2)-weighted images was observed as a hypointense lesion.
  • [MeSH-major] Androgen Antagonists / administration & dosage. Chlormadinone Acetate / administration & dosage. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Regression, Spontaneous

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497498.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0SY050L61N / Chlormadinone Acetate; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


8. Santelli L, Ramondo G, Della Puppa A, Ermani M, Scienza R, d'Avella D, Manara R: Diffusion-weighted imaging does not predict histological grading in meningiomas. Acta Neurochir (Wien); 2010 Aug;152(8):1315-9; discussion 1319
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study aims to verify the reliability of diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) measurements to differentiate benign from atypical/malignant meningiomas and among different sub-types.
  • DWI signal intensity of tumors was classified as hypo-, iso- or hyper-intense to grey matter.
  • RESULTS: Meningiomas were histologically graded as malignant (1%), atypical (21.5%) and benign (77.5%).
  • Meningothelial, transitional and fibrous were the most frequent benign sub-types (44, 16 and 10 cases, respectively).
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain / pathology. Diagnosis, Differential. Female. Humans. Male. Meninges / pathology. Middle Aged. Observer Variation. Predictive Value of Tests. Prognosis. Reproducibility of Results. Severity of Illness Index

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428902.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  •  go-up   go-down


9. Happle C, Wetzke M, Hermann EJ, Krauss JK, Hartmann H, Lücke T: ['Cases against KiSS': a diagnostic algorithm for children with torticollis]. Klin Padiatr; 2009 Dec;221(7):430-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present two infants with brain tumours who developed torticollis and further neurological findings such as ataxia and reflex differences.
  • In both cases, symptoms caused by the tumour were interpreted as "KiSS-syndrome", and appropriate diagnostics and therapy were delayed for months.
  • Whereas most cases are benign, there is a long list of serious differential diagnoses for torticollis in infants.
  • [MeSH-major] Algorithms. Astrocytoma / diagnosis. Cerebellar Neoplasms / diagnosis. Cervical Vertebrae. Ganglioglioma / diagnosis. Magnetic Resonance Imaging. Neoplasms, Second Primary / diagnosis. Spinal Diseases / diagnosis. Torticollis / etiology
  • [MeSH-minor] Child, Preschool. Diagnostic Errors. Gait Disorders, Neurologic / etiology. Humans. Infant. Male. Microsurgery. Neoplasm, Residual / diagnosis. Neurologic Examination. Postoperative Complications / diagnosis. Reoperation. Syndrome

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 20013566.001).
  • [ISSN] 1439-3824
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Liu J, Zheng S, Yu JK, Yu XB, Liu WG, Zhang JM, Hu X: [Establishment of diagnostic model of cerebrospinal protein fingerprint pattern for glioma and its clinical application]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Mar;34(2):141-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Seventy-five samples of cerebrospinal fluid from patients with gliomas, benign brain tumors and mild brain traumas were collected.
  • A total of 50 samples from gliomas and non-brain-tumors were divided into training sets (33 cases including 17 gliomas and 16 non-brain-tumors) and testing sets (17 cases including 5 gliomas and 12 non-brain-tumors).
  • The cerebrospinal proteins bound to H4 chip were detected by SELDI-TOF MS, the profiles of cerebrospinal protein were gained and then analyzed with artificial neural network algorithm (ANN); and the diagnostic model of cerebrospinal protein profiles for differentiating gliomas from non-brain-tumors was established.
  • Forty-seven of cerebrospinal samples of gliomas and benign brain tumors were divided into training sets (31 cases including 13 gliomas and 18 benign brain tumors) and testing sets (16 cases including 9 gliomas and 7 benign brain tumors), the diagnostic model of cerebrospinal protein profiles for differentiating gliomas from benign brain tumors was established based on the same method.
  • RESULT: The diagnostic model of cerebrospinal protein profiles for differentiating gliomas from non-brain-tumors was established and was challenged with the test set randomly, the sensitivity and specificity were 100% and 91.7%, respectively.
  • The cerebrospinal protein profiling model for differentiating gliomas from benign brain tumors was also developed and was challenged with the test set randomly, the sensitivity and specificity were 88.9%, and 100%, respectively.
  • CONCLUSION: The technology of SELDI-TOF MS which combined with analysis tools of bioinformatics is a novel effective method for screening and identifying tumor biomarkers of gliomas and it may provide a new approach for the clinical diagnosis of glioma.
  • [MeSH-major] Brain Neoplasms / cerebrospinal fluid. Cerebrospinal Fluid Proteins / genetics. Glioma / cerebrospinal fluid. Peptide Mapping / standards
  • [MeSH-minor] Adult. Aged. Algorithms. Biomarkers, Tumor. Diagnosis, Differential. Female. Humans. Male. Meningioma / cerebrospinal fluid. Meningioma / diagnosis. Middle Aged. Neural Networks (Computer). Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812888.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cerebrospinal Fluid Proteins
  •  go-up   go-down


11. Kuo YH, Edgar MA, Luther N, Schwartz TH: Novel low-grade glioneuronal neoplasm presenting in an octogenarian: case report and review of the literature. Clin Neurol Neurosurg; 2006 Jun;108(4):426-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel low-grade glioneuronal neoplasm presenting in an octogenarian: case report and review of the literature.
  • Glioneuronal neoplasms are rare tumors that typically affect patients in the first three decades of life.
  • Since the publication of the World Health Organization (WHO) 2000 classification of tumors, further variants of these tumors have been reported.
  • MRI and CT scan revealed a ring-enhancing bihemispheric lesion in the premotor cortex consistent with a malignant primary brain tumor crossing the corpus collosum.
  • Histopathologic studies revealed a mixed glioneuronal tumor with benign characteristics.
  • A craniotomy was performed and the tumor was resected.
  • Glioneuronal tumors are extremely uncommon in the octogenarian population, however, it is important to include them in the differential diagnosis of intracerebral masses.
  • Radiographically, these lesions can mimic more aggressive primary brain tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Neuroglia / pathology. Neurons / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16758540.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 23
  •  go-up   go-down


12. Mahfouz S, Aziz AA, Gabal SM, el-Sheikh S: Immunohistochemical study of CD99 and EMA expression in ependymomas. Medscape J Med; 2008;10(2):41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the central nervous system (CNS) represent a unique, heterogeneous population of neoplasms and include both benign and malignant tumors.
  • The present study was carried out on a total of 79 archival cases of ependymal tumors in addition to a variety of other primary CNS tumors.
  • Upon comparing with other CNS tumors (41 cases), it was found that CD99 could differentiate between ependymomas and nonependymal tumors, but intensity and pattern of staining were of no consequence in determining variant type or degree of histologic aggressiveness.
  • Thus, EMA was found to be of little value in the diagnosis of ependymoma and in the differentiation between different types and grades.
  • CD99 can hence be recommended for use as a good marker for differentiation between ependymal and other CNS tumors.
  • EMA expression and pattern of distribution, on the other hand, cannot be employed to determine the type of variant or the degree of tumor aggressiveness, and hence cannot predict the behavior of ependymal neoplasms.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Cell Adhesion Molecules / analysis. Ependymoma / diagnosis. Ependymoma / metabolism. Mucin-1 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Proteins / analysis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):25-31 [10937045.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):125-9 [11396629.001]
  • [Cites] Diagn Cytopathol. 2002 Apr;26(4):247-50 [11933271.001]
  • [Cites] J Neurooncol. 2002 May;58(1):13-9 [12160136.001]
  • [Cites] Exp Mol Med. 2002 Jul 31;34(3):177-83 [12216109.001]
  • [Cites] Acta Neuropathol. 2003 Oct;106(4):385-8 [12898159.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):980-91 [14559980.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):517-23 [14585232.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1230-7 [15022291.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Mar;63(3):185-92 [15055442.001]
  • [Cites] Neuropathol Appl Neurobiol. 1988 May-Jun;14(3):197-205 [3405393.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6127-31 [2844401.001]
  • [Cites] Acta Neuropathol. 1989;78(3):325-8 [2763805.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(2):97-103 [1695040.001]
  • [Cites] Arch Pathol Lab Med. 1990 Sep;114(9):956-60 [2390011.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1886-93 [1848471.001]
  • [Cites] Acta Neuropathol. 1991;82(3):208-16 [1718129.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):486-94 [7513503.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):189-93 [15690137.001]
  • [Cites] Brain Tumor Pathol. 2004;21(1):17-21 [15696964.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2598-605 [15861411.001]
  • [Cites] Histopathology. 2007 Feb;50(3):365-70 [17257132.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):255-70 [12187959.001]
  • [Cites] Acta Neuropathol. 1997 Mar;93(3):310-6 [9083565.001]
  • [Cites] Neuropathology. 2004 Dec;24(4):330-5 [15641594.001]
  • [Cites] Pathol Res Pract. 2004;200(10):717-25 [15648610.001]
  • (PMID = 18382710.001).
  • [ISSN] 1934-1997
  • [Journal-full-title] Medscape journal of medicine
  • [ISO-abbreviation] Medscape J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Mucin-1; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2270873
  •  go-up   go-down


13. De Wever W, Bruyeer E, Demaerel P, Wilms G, Coolen J, Verschakelen J: Staging of lung cancer. Do we need a diagnostic CT of the brain after an integrated PET/CT for the detection of brain metastases? JBR-BTR; 2010 Mar-Apr;93(2):71-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging of lung cancer. Do we need a diagnostic CT of the brain after an integrated PET/CT for the detection of brain metastases?
  • Brain CT has been recommended in staging of patients with lung cancer because of its usefulness in the detection of metastases.
  • Purpose of this study is to examine if a diagnostic brain CT (CT,) can be obviated when an integrated PET/CT (PET/CT) is available.
  • 87 consecutive patients underwent a diagnostic brain CT and a whole-body PET/CT within a period of 3 weeks to stage a known primary tumour.
  • CT examinations were evaluated by two experienced neuroradiologists on the detection of brain lesions (benign and malignant).
  • Considering the CT, as standard of reference, sensitivity, specificity, PPV, NPV and accuracy for the brain CT of PET/CT (CT2) and PET/CT were respectively 83%, 96%, 77%, 97%, 94% and 69%, 98%, 90%, 95%, 94%.
  • Considering the clinical diagnosis as standard of reference these figures were for CT1, CT2 and PET/CT respectively 80%, 100%, 100%, 96%, 96% and 66%, 95%, 77%, 93%, 90% and 66%, 97%, 83%, 93%, 91%.
  • The comparison of the additional CT in PET/CT with a diagnostic CT of the brain did not yield a statistical difference in the detection of brain lesions despite the inferior quality of the CT component of PET/CT.
  • A diagnostic brain CT can be obviated when a PET/CT is available.
  • [MeSH-major] Brain Neoplasms / radiography. Brain Neoplasms / secondary. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Brain / radiography. Contrast Media. Female. Humans. Male. Middle Aged. Neoplasm Staging. Observer Variation. Radiographic Image Enhancement / methods. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity. Whole Body Imaging / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524514.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


14. Fu YJ, Morota N, Nakagawa A, Takahashi H, Kakita A: Neurocutaneous melanosis: surgical pathological features of an apparently hamartomatous lesion in the amygdala. J Neurosurg Pediatr; 2010 Jul;6(1):82-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurocutaneous melanosis (NCM) is a rare, congenital phakomatosis characterized by the presence of congenital melanocytic nevi and a benign or malignant pigmented cell tumor of the leptomeninges of the CNS.
  • Based on the histopathological features, the parenchymal lesion appeared to be hamartomatous in nature rather than a neoplasm, involving aberrant migration of melanocytes into the developing neuroepithelial tissue.
  • [MeSH-major] Amygdala / pathology. Amygdala / surgery. Brain Diseases / pathology. Brain Diseases / surgery. Epilepsy, Temporal Lobe / pathology. Epilepsy, Temporal Lobe / surgery. Hamartoma / pathology. Hamartoma / surgery. Magnetic Resonance Imaging. Melanosis / pathology. Melanosis / surgery. Neurocutaneous Syndromes / pathology. Neurocutaneous Syndromes / surgery. Nevus, Pigmented / pathology. Nevus, Pigmented / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Tomography, X-Ray Computed
  • [MeSH-minor] Anterior Temporal Lobectomy. Child. Female. Hippocampus / pathology. Hippocampus / surgery. Humans. Malformations of Cortical Development / diagnosis. Malformations of Cortical Development / pathology. Malformations of Cortical Development / surgery. Melanocytes / pathology. Neurons / pathology. Temporal Lobe / pathology


15. Prabhu SS, Bruner JM: Large oculomotor schwannoma presenting as a parasellar mass: A case report and literature review. Surg Neurol Int; 2010;1:15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The common site of tumor occurrence in this nerve is the segment within the interpeduncular cistern and the cavernous sinus.
  • The radiological features of the mass were more consistent with a medial sphenoid wing meningioma causing brain stem compression.
  • Complete resection of the tumor was achieved via a left pterional approach.
  • CONCLUSION: The management of these large benign tumors with brain stem compression includes surgical resection.
  • Intraoperative anatomical preservation of the third nerve was impossible given its course in the tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1992 Sep;38(3):216-24 [1440207.001]
  • [Cites] Neurochirurgie. 1992;38(3):183-7 [1461338.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Feb;30(2):132-6 [1695335.001]
  • [Cites] Clin Neurol Neurosurg. 1990;92(4):333-5 [1963824.001]
  • [Cites] Br J Neurosurg. 1990;4(1):69-72 [2185790.001]
  • [Cites] Surg Neurol. 1985 Sep;24(3):275-8 [4023908.001]
  • [Cites] Surg Neurol. 2007 Jan;67(1):83-8; discussion 88 [17210311.001]
  • [Cites] J Neurosurg. 1982 Jun;56(6):854-6 [7077388.001]
  • [Cites] J Neurosurg. 1982 Oct;57(4):563-5 [7108608.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(11):1147-51 [9870060.001]
  • [Cites] Br J Neurosurg. 2003 Apr;17(2):168-73 [12820761.001]
  • [Cites] Skull Base Surg. 1994;4(4):219-26 [17171175.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1981 May;44(5):397-401 [7021770.001]
  • (PMID = 20657696.001).
  • [ISSN] 2152-7806
  • [Journal-full-title] Surgical neurology international
  • [ISO-abbreviation] Surg Neurol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2908360
  • [Keywords] NOTNLM ; Meningioma / oculomotor schwannoma / skull base
  •  go-up   go-down


16. Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, Wu YC, Huang CY: VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS One; 2009;4(4):e5052
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite recent advances in diagnosis and treatment, the mortality rates with an overall 5-year survival of only 15%.
  • METHODOLOGY/PRINCIPAL FINDINGS: To identify novel lung adenocarcinoma-associated /metastasis genes and to clarify the underlying molecular mechanisms of these targets in lung cancer progression, we created a bioinformatics scheme consisting of integrating three gene expression profile datasets, including pairwise lung adenocarcinoma, secondary metastatic tumors vs. benign tumors, and a series of invasive cell lines.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Cycle Proteins / physiology. Lung Neoplasms / pathology. Neoplasm Invasiveness. Neoplasm Metastasis. Nuclear Proteins / physiology. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Up-Regulation / physiology. Vascular Endothelial Growth Factor A / physiology
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Enzyme Activation. Gene Knockdown Techniques. Humans. Microscopy, Fluorescence. RNA, Messenger / genetics. RNA, Small Interfering. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2002 Apr;1(3):219-27 [12086857.001]
  • [Cites] Nature. 1999 Dec 2;402(6761):483-7 [10591207.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] J Pathol. 2003 Jul;200(3):336-47 [12845630.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):660-4 [12869408.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1171-7 [14641020.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):294-300 [14656735.001]
  • [Cites] Mol Ther. 2004 Apr;9(4):510-8 [15093181.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32592-602 [15145941.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6865-71 [15501963.001]
  • [Cites] Apoptosis. 2004 Nov;9(6):667-76 [15505410.001]
  • [Cites] Cancer Metastasis Rev. 1996 Dec;15(4):507-25 [9034607.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):64-8 [9036871.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Sep;17(3):353-60 [9308922.001]
  • [Cites] Br J Cancer. 1997;76(8):1041-5 [9376264.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):589-93 [11212254.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3986-97 [11358816.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5223-30 [11431363.001]
  • [Cites] Langenbecks Arch Surg. 2001 Jul;386(4):293-301 [11466572.001]
  • [Cites] FASEB J. 2001 Sep;15(11):1953-62 [11532975.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 19;93(18):1392-400 [11562390.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3410-5 [11705856.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):558-63 [11870537.001]
  • [Cites] Science. 2002 May 31;296(5573):1655-7 [12040186.001]
  • [Cites] J Biol Chem. 1997 Dec 19;272(51):32521-7 [9405464.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1483-7 [9626466.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10002-7 [10187776.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73 [10508818.001]
  • [Cites] Lung. 2004;182(3):151-62 [15526754.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Nov 15;170(10):1088-94 [15317667.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Dev Cell. 2005 Oct;9(4):477-88 [16198290.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 16;338(2):830-8 [16256070.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7443-54 [16288291.001]
  • [Cites] Mol Cell. 2005 Nov 23;20(4):539-50 [16307918.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):46-51 [16397214.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):306-14 [16330671.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):480-6 [16170351.001]
  • [Cites] Genomics. 2006 Feb;87(2):243-53 [16406728.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):609-21 [16158046.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1354-62 [16452189.001]
  • [Cites] Cancer Lett. 2006 Apr 8;235(1):53-9 [15899546.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):603-5 [16582622.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):23285-95 [16787925.001]
  • [Cites] Mol Biol Cell. 2006 Sep;17(9):3881-96 [16790497.001]
  • [Cites] Curr Opin Investig Drugs. 2007 Feb;8(2):140-9 [17328230.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):7758-69 [17178724.001]
  • [Cites] Oncogene. 2007 Jun 21;26(29):4272-83 [17237822.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Aug;63(2):172-82 [17540577.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Behav Brain Res. 2002 Nov 15;136(2):489-501 [12429412.001]
  • (PMID = 19337377.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cep55 protein, human; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Vascular Endothelial Growth Factor A; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2659802
  •  go-up   go-down


17. Coluccia D, Fandino J, Fujioka M, Cordovi S, Muroi C, Landolt H: Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas. Acta Neurochir (Wien); 2010 Oct;152(10):1711-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraoperative 440 nm fluorescence was applied periodically during and at the end of resection in order to detect tumor-infiltrated sites.
  • The fluorescence of the tumor was evaluated intraoperatively by the surgeon and confirmed by subsequent video analysis.
  • RESULTS: A total of 32 (97%) patients presented with benign meningiomas (WHO I-II).
  • 5-ALA-induced fluorescence of the tumor was confirmed in a total of 31 (94%) patients.
  • The fluorescence did not correlate with the histological findings (n = 30 WHO I-II, n = 1 WHO grade III) or with preoperative brain edema and administration of steroids.
  • [MeSH-major] Aminolevulinic Acid. Fluorescence. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Monitoring, Intraoperative / methods. Photosensitizing Agents
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / diagnosis. Neoplasm Recurrence, Local / prevention & control. Preoperative Care / methods. Ultraviolet Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20535506.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


18. Wang F, Wang Z, Yao W, Xie H, Xu J, Tian L: Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging. J Nucl Med; 2007 Sep;48(9):1442-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Forty-four consecutive patients with suspected pulmonary neoplasms underwent tomographic (99m)Tc-octreotide scintigraphy and (18)F-FDG coincidence imaging using the same gantry.
  • The tumor-to-normal tissue tracer values for both (99m)Tc-octreotide and (18)F-FDG were determined using region of interests and expressed as T/N(r) and T/N(m), respectively.
  • Final diagnosis was confirmed by histopathologic analysis or clinical follow-up.
  • Thirteen of the 44 patients had benign lung lesions.
  • In the 31 patients with malignant tumors, all 38 abnormal lymph nodes in 20 patients showed abnormal high focal uptake of (18)F-FDG; only 7 patients with 10 regional lymph adenopathies showed moderate uptake of (99m)Tc-octreotide.
  • Thirteen patients with 39 distant sites of abnormal uptake visualized (imaging stage IV) with (99m)Tc-octreotide included 2 patients with brain metastases, 6 patients with pleural invasion and multiple bone metastasis, 2 patients with contralateral internal lung metastasis and pleural invasion, and 3 patients with only multiple bone metastasis.
  • The final diagnosis was confirmed by histopathology or clinical follow-up.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Octreotide / analogs & derivatives. Organotechnetium Compounds. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704242.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 99mTc-octreotide; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; RWM8CCW8GP / Octreotide
  •  go-up   go-down


19. Ferchichi L, Bellil S, Ben Hammouda K, Bellil K, Mekni A, Bettaieb I, Haouet S, Khaldi MM, Zitouna K, Kchir N: Anaplastic secretory meningioma: a case report. Pathologica; 2006 Apr;98(2):153-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secretory meningiomas are rare histological subtypes of meningiomas with benign biological behaviour.
  • In this study, the authors describe the first case of secretory meningioma with many mitotic figures and brain invasion, and discuss the clinicopathologic features including immunohistochemical staining profile and ultrastructural appearance of this tumour.
  • A case of a 54-year-old man diagnosed with an intracranial tumour located in the left frontal lobe is presented.
  • On pre-contrast CT scans, the tumour was hypodense and the contrast enhancement was marked in the pseudo membrane.
  • The tumour was partially removed.
  • The histological diagnosis was secretory meningioma with many mitotic figures, a high MIB-1 labeling index and a brain invasion.
  • [MeSH-major] Frontal Lobe / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Carcinoembryonic Antigen / analysis. Combined Modality Therapy. Cranial Irradiation. Humans. Keratins / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Mitotic Index. Mucin-1 / analysis. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929789.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


20. Chou CH, Lieu AS, Wu CH, Chang LK, Loh JK, Lin RC, Chen WJ, Liao HD, Fu WS, Chang CS, Lin CC, Hsu CM, Chio CC, Howng SL, Hong YR: Differential expression of hedgehog signaling components and Snail/E-cadherin in human brain tumors. Oncol Rep; 2010 Nov;24(5):1225-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of hedgehog signaling components and Snail/E-cadherin in human brain tumors.
  • However, the role of Hh signaling components and Snail/E-cadherin in brain tumors is not yet fully understood.
  • We analyzed the expression of Hh signaling components and Snail/E-cadherin in 69 brain tumors by reverse transcription-polymerase chain reaction (RT-PCR).
  • The data showed that overexpression of Smo (35/69), Ptch (50/69), Gli1 (56/69), Gli2 (29/69) and N-myc (39/69) might contribute to brain tumorigenesis.
  • Our results also indicated that Snail and E-cadherin showed opposing expression in malignant tumors (high grade astrocytoma and metastasis).
  • Snail and E-cadherin showed less correlation in benign brain tumors.
  • Taken together, our results demonstrate that Hh signaling components, the expression and mutations of Snail and the expression of E-cadherin may play an important role in human brain tumorigenesis.
  • [MeSH-major] Brain Neoplasms / genetics. Cadherins / genetics. Hedgehog Proteins / genetics. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878114.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cadherins; 0 / Hedgehog Proteins; 0 / Transcription Factors; 0 / snail family transcription factors
  •  go-up   go-down


21. Tena-Suck ML, Salinas-Lara C, Arce-Arellano RI, Rembao-Bojórquez D, Morales-Espinosa D, Sotelo J, Arrieta O: Clinico-pathological and immunohistochemical characteristics associated to recurrence/regrowth of craniopharyngiomas. Clin Neurol Neurosurg; 2006 Oct;108(7):661-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Craniopharyngioma is a rare, benign epithelial brain tumor of the suprasellar region with a high rate of recurrence.
  • METHODS: We compared recurrence/regrowth of the tumors with the clinico-pathological characteristics, vascular density, cell proliferation index, and immunohistochemical profile (cytokeratins, epithelial membrane antigen [EMA], carcinoembrionary antigen [CEA], and laminin) of 47 patients with craniopharyngioma followed for more than 5 years.
  • RESULTS: Tumors were adamantinomatous in 42 cases (89%) and papillary squamous in 5 cases (11%).
  • The cell proliferation index and vascular density were greater in adamantinomatous than in papillary tumors (22+/-6 versus 17+/-3, p=0.05; and 21+/-3 versus 17+/-3, p=0.037, respectively); they were neither related to recurrence nor to regrowth.
  • No significant differences were found between adamantinomatous and papillary tumors regarding the presence of cytokeratin, laminin, CEA or glial fibrillary acidic protein (GFAP).
  • Residual tumor after surgery, whorl-like arrays (p=0.04) and immunoreactivity for p53 (p=0.022) were significantly related to recurrence/regrowth.
  • CONCLUSIONS: Residual tumor after surgery, immunoreactivity to p53 and presence of whorl-like arrays are associated to recurrence/regrowth of craniopharyngioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / physiopathology. Craniopharyngioma / diagnosis. Craniopharyngioma / physiopathology. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / metabolism. Cell Proliferation. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Keratins / metabolism. Laminin / metabolism. Male. Mucin-1 / metabolism. Neovascularization, Pathologic / diagnosis. Neovascularization, Pathologic / epidemiology. Neovascularization, Pathologic / physiopathology. Predictive Value of Tests. Prognosis. Radiotherapy / statistics & numerical data. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16500745.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Laminin; 0 / Mucin-1; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins
  •  go-up   go-down


22. McCarthy BJ, Kruchko C, Central Brain Tumor Registry of the United States: Consensus conference on cancer registration of brain and central nervous system tumors. Neuro Oncol; 2005 Apr;7(2):196-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consensus conference on cancer registration of brain and central nervous system tumors.
  • The passage of Public Law 107-260, the Benign Brain Tumor Cancer Registries Amendment Act, in October 2002 has made the collection of all primary brain tumors a reality.
  • However, at the first Consensus Conference on Brain Tumor Definition for Registration in 2002, and during the development of training materials for benign brain tumor collection, several issues were identified that were tabled for future discussion.
  • These and other issues were addressed at the subsequent 2003 Consensus Conference on Cancer Registration of Brain and Central Nervous System Tumors, at which the Central Brain Tumor Registry of the United States facilitated a discussion among epidemiologists, neurosurgeons, and neuropathologists.
  • (1) amend the histology coding scheme for cysts and tumor-like lesions that currently have a code in the third edition of the International Classification of Disease for Oncology (ICDO), (2) collect data on all instances of specific cysts and tumor-like lesions that are located in brain and other CNS sites but currently lack ICDO codes, (3) establish a new ICDO topography site for skull base tumors for the brain and CNS, and (4) collect data on genetic syndromes in patients diagnosed with brain or CNS tumors.
  • Because classification of primary intracranial and other CNS tumors is dynamic, and the registration and coding of these tumors will need to be periodically reviewed.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / pathology. Registries

  • Genetic Alliance. consumer health - Brain Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1998 Jul 15;90(14):1039-71 [9672254.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):134-45 [11916506.001]
  • (PMID = 15831238.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  • [Other-IDs] NLM/ PMC1871892
  •  go-up   go-down


23. Matsuo Y, Kamitani T: Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma. PLoS One; 2010;5(5):e10481
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parkinson's disease is a neurodegenerative disorder that is caused by mutation of alpha-synuclein or other genes.
  • CONCLUSIONS/SIGNIFICANCE: The Parkinson's disease-related protein, alpha-synuclein, is expressed in both malignant and benign melanocytic lesions, such as melanomas and nevi.
  • Although alpha-synuclein cannot be used to distinguish between malignant and benign melanocytic skin lesions, it might be a useful biomarker for the diagnosis of metastatic melanoma.
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Cell Line, Tumor. Female. Humans. MART-1 Antigen. Male. Melanins / metabolism. Middle Aged. Neoplasm Proteins / metabolism. Nevus / metabolism. Nevus / pathology. Pigmentation. Retinoblastoma / metabolism. Retinoblastoma / pathology. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2001 Mar;54(3):196-200 [11253130.001]
  • [Cites] Neurology. 2009 Oct 20;73(16):1286-91 [19841380.001]
  • [Cites] J Neurosci. 2002 Apr 15;22(8):3090-9 [11943812.001]
  • [Cites] Nat Rev Neurosci. 2002 Jul;3(7):531-41 [12094209.001]
  • [Cites] Traffic. 2002 Sep;3(9):678-93 [12191019.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):217-23 [14991540.001]
  • [Cites] J Immunother. 1998 Jan;21(1):27-31 [9456433.001]
  • [Cites] Cancer. 1999 Feb 25;87(1):37-42 [10096358.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):617-27 [10440689.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):201-5 [15583688.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):687-701 [15721476.001]
  • [Cites] J Cell Sci. 2005 Aug 1;118(Pt 15):3523-30 [16030137.001]
  • [Cites] Epidemiology. 2006 Sep;17(5):582-7 [16837822.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Oct;8(10):786-97 [17878918.001]
  • [Cites] Orphanet J Rare Dis. 2007;2:43 [17980020.001]
  • [Cites] Nat Clin Pract Oncol. 2009 Feb;6(2):105-17 [19107110.001]
  • [Cites] Virchows Arch. 2009 May;454(5):505-11 [19352698.001]
  • [Cites] Biochim Biophys Acta. 2009 Jul;1792(7):616-24 [18955133.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1039-46 [11474288.001]
  • (PMID = 20463956.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01 AG024497
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanins; 0 / Neoplasm Proteins; 0 / alpha-Synuclein
  • [Other-IDs] NLM/ PMC2864738
  •  go-up   go-down


24. Naumann IC, Cordes SR: Giant basal cell carcinoma of the forehead with extensive intracranial involvement. Ann Otol Rhinol Laryngol; 2007 Sep;116(9):663-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite its fairly benign growth pattern, BCC should never be underestimated, and care should be taken not only in the complete primary excision but also in cancer surveillance.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Forehead. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neurosurgical Procedures / methods. Reconstructive Surgical Procedures / methods. Severity of Illness Index. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17926588.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Naydenov E, Tzekov C, Minkin K, Nachev S, Marinov M: [Malignant progression of an anaplastic ganglioglioma into a glioblastoma multiforme--report on two cases and review of the literature]. Khirurgiia (Sofiia); 2009;(2-3):69-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Ganglioglioma is an uncommon type of primary brain tumors.
  • In most of the cases the tumor demonstrates benign clinical behaviour with long-term patients' survival.
  • The tumor was excised partially and the histological result was anaplastic ganglioglioma (World Health Organization - WHO. gr. III).
  • A local tumor recurrence was found and the patient underwent second operative intervention with gross total tumor resection.
  • An involvement of the contralateral cerebral hemisphere was found on control CT-scan ten months later.
  • The patient died after one month, 23 months after her initial diagnosis.
  • MRI data for large, heterointense tumor lesion in the left frontal lobe was found.
  • A subtotal tumor removal was made.
  • Data for additional local tumor growth was found on control CT-scan one month later.
  • 20 months after the initial diagnosis.
  • The tumor behaviour may vary between the patients in spite of the similar histological characteristics which indicates the possible presence of different tumor subtypes.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology. Glioblastoma / pathology. Neoplasm Recurrence, Local / pathology


26. McCarthy BJ, Schellinger KA, Propp JM, Kruchko C, Malmer B: A case for the worldwide collection of primary benign brain tumors. Neuroepidemiology; 2009;33(3):268-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case for the worldwide collection of primary benign brain tumors.
  • BACKGROUND: Incidence data on malignant tumors are reported by the International Agency for Research on Cancer, with 189,485 new malignant brain tumors globally in 2002.
  • However, collection and reporting of benign brain tumors are not universal.
  • The objective here is to encourage the collection of primary benign brain tumors worldwide.
  • METHODS: Worldwide numbers of primary benign brain tumors were estimated through published articles and cancer registry reports presenting directly or indirectly reported benign incidence rates or frequencies for regions or countries.
  • RESULTS: An estimated 186,678 benign brain tumors were diagnosed worldwide in 2002.
  • The estimated numbers of benign brain tumors were higher in females than males (105,918 vs. 80,759).
  • Since many countries do not report primary benign brain tumors, the incidence rate estimates vary significantly by region.
  • CONCLUSIONS: This is the first survey to assess worldwide numbers of benign brain tumors.
  • However, the estimated number of benign brain tumors approximately equals, and could exceed, the number of malignant brain tumors globally.
  • Registration of primary benign brain histologies in different geographical areas and ethnicities could provide clues to the underlying causes of these tumors.
  • [MeSH-major] Brain Neoplasms / epidemiology. Global Health


27. Asioli S, Senetta R, Maldi E, D'Ambrosio E, Satolli MA, Bussolati G, Cassoni P: "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung. Virchows Arch; 2007 May;450(5):591-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung.
  • Lung "metastases" of benign meningiomas are rarely described events of biological and clinical interest.
  • Anamnesis revealed that the patient underwent a surgical resection of cerebral meningioma 12 years before.
  • The morphological and immunohistochemical features of this lesion, together with the similarity with the original cerebral tumour and its indolent evolution, led to a final diagnosis of "benign" meningioma metastatic to the lung.
  • They represent a typical example of "benign" tumours that may implant to the lung similar to other tumours, definitely considered benign but reported to rarely present unusual secondary localization.
  • [MeSH-major] Brain Neoplasms / pathology. Lung Neoplasms / secondary. Meningioma / secondary
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Neoplasm Metastasis / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Mar 1;67(5):1412-7 [1991305.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 Jan-Feb;8(1):127-30 [3101455.001]
  • [Cites] Virchows Arch. 2001 Aug;439(2):196-200 [11561761.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):976 [9255263.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):194-8 [12546373.001]
  • [Cites] J Neurosurg. 1985 May;62(5):763-6 [3989597.001]
  • [Cites] Arch Pathol Lab Med. 1997 Jun;121(6):631-6 [9199633.001]
  • [Cites] Semin Diagn Pathol. 1995 May;12(2):193-206 [7638451.001]
  • [Cites] J Thorac Imaging. 2002 Jul;17 (3):227-9 [12082375.001]
  • [Cites] Clin Neurol Neurosurg. 1990;92(2):152-4 [2163798.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):207-14 [15043310.001]
  • [Cites] J Cutan Pathol. 1987 Jun;14(3):129-46 [3301927.001]
  • [Cites] Adv Clin Path. 2000 Jan;4(1):35-9 [10936897.001]
  • [Cites] Am J Surg Pathol. 1988 Mar;12(3):167-75 [2830799.001]
  • [Cites] J Laryngol Otol. 2004 Sep;118(9):724-6 [15509374.001]
  • [Cites] J Comput Assist Tomogr. 2001 Mar-Apr;25(2):311-3 [11242234.001]
  • [Cites] Neurosurgery. 1992 Dec;31(6):1113-6; discussion 1116 [1470323.001]
  • [Cites] Dtsch Med Wochenschr. 2004 Sep 3;129(36):1854-7 [15368156.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):579-82 [11801758.001]
  • [Cites] Ann Thorac Surg. 1996 Jun;61(6):1823-4 [8651794.001]
  • [Cites] Hum Pathol. 1991 May;22(5):469-74 [1709609.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Aug;88(2):170-6 [10468461.001]
  • [Cites] Neurosurgery. 1987 May;20(5):688-94 [3601014.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):453-60 [9130993.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):425-9 [10208464.001]
  • [Cites] Surg Neurol. 1988 May;29(5):410-3 [3363477.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):86-8 [12629059.001]
  • (PMID = 17431673.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


28. Finger PT, Kurli M, Reddy S, Tena LB, Pavlick AC: Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol; 2005 Oct;89(10):1270-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PET/CT scans were used as a screening tool at the time of their initial diagnosis.
  • Brain involvement was also present in one patient.
  • In seven patients (13.4%) PET/CT imaging detected benign lesions in the bone, lung, lymph nodes, colon, and rectum.
  • [MeSH-major] Choroid Neoplasms / pathology. Melanoma / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / radiography. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Female. Fluorodeoxyglucose F18. Humans. Liver Neoplasms / radiography. Liver Neoplasms / radionuclide imaging. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography / methods. Radiopharmaceuticals. Spinal Neoplasms / radiography. Spinal Neoplasms / radionuclide imaging. Spinal Neoplasms / secondary. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 2001 May;119(5):670-6 [11346394.001]
  • [Cites] Eye (Lond). 1998;12 ( Pt 6):945-8 [10325992.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1797-803 [14602862.001]
  • [Cites] JAMA. 2003 Dec 24;290(24):3199-206 [14693872.001]
  • [Cites] J Nucl Med. 2004 Jan;45 Suppl 1:72S-81S [14736838.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):272-8 [14960647.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2438-44 [15197206.001]
  • [Cites] Br J Ophthalmol. 2004 Aug;88(8):1095-7 [15258035.001]
  • [Cites] Surv Ophthalmol. 2004 Sep-Oct;49(5):537-40 [15325198.001]
  • [Cites] Cancer. 1974 Oct;34(4):1001-4 [4424282.001]
  • [Cites] Arch Ophthalmol. 1982 Jun;100(6):939-40 [7092632.001]
  • [Cites] Arch Ophthalmol. 1986 Nov;104(11):1624-5 [3778275.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):383-9; discussion 390 [2023760.001]
  • [Cites] J Invest Dermatol. 1993 Mar;100(3):326S-331S [8440916.001]
  • [Cites] Arch Ophthalmol. 1996 Jan;114(1):107-8 [8540843.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2589-95 [9215829.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Jun;16(2):201-8 [9261748.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1151-9 [10091801.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2500-7 [12815135.001]
  • (PMID = 16170114.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC1772897
  •  go-up   go-down


29. De Marinis L, Fusco A, Bianchi A, Aimaretti G, Ambrosio MR, Scaroni C, Cannavo S, Di Somma C, Mantero F, degli Uberti EC, Giordano G, Ghigo E: Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report. J Endocrinol Invest; 2006 Jun;29(6):516-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report.
  • It may occur after neurosurgical treatment of brain tumors arising near sella turcica.
  • The aim of this study was to evaluate pituitary function in particular GH deficiency (GHD) in patients submitted to neurosurgery for benign tumors of the central nervous system (CNS) not involving hypothalamic-pituitary region.
  • We observed 37 patients with benign brain tumors [13 males, 24 females, age: 54.6+/-13.9 yr; body mass index (BMI): 25.1+/-4.0 kg/m2] performing a basic evaluation of the pituitary function and a dynamic test of the GH/IGF-I axis [GHRH (1 microg/kg iv)+arginine (0.5 g/kg iv) test] for 3 and 12 months after the neurosurgical treatment.
  • This data suggests that hypopituitarism of various degree may develop in patients who are submitted to neurosurgery for primary brain tumors, even far from hypothalamic-pituitary region.
  • [MeSH-major] Brain Neoplasms / surgery. Hypopituitarism / etiology. Postoperative Complications

  • Genetic Alliance. consumer health - Hypopituitarism.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1998 Jul 11;352(9122):127-34 [9672293.001]
  • [Cites] Endocrine. 2001 Jun;15(1):29-38 [11572322.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Dec;90(12):6355-60 [16144946.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Sep;61(3):320-6 [15355447.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1615-8 [9589665.001]
  • [Cites] J Endocrinol Invest. 2004 Dec;27(11):1048-54 [15754737.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:26-33 [15761229.001]
  • [Cites] J Cereb Blood Flow Metab. 1998 Aug;18(8):833-9 [9701344.001]
  • [Cites] Horm Res. 2003;59 Suppl 1:1-11 [12566714.001]
  • [Cites] Neuropathol Appl Neurobiol. 1997 Aug;23(4):307-14 [9292869.001]
  • [Cites] Expert Opin Pharmacother. 2004 May;5(5):1023-31 [15155105.001]
  • [Cites] Neurologist. 2004 May;10(3):113-30 [15140272.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):662-9 [10603007.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S118-24 [15135792.001]
  • [Cites] Neurosurg Clin N Am. 2003 Oct;14(4):571-91 [15024802.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S114-7 [15135791.001]
  • [Cites] Eur J Pediatr. 1997 Oct;156(10):764-9 [9365064.001]
  • [Cites] Curr Opin Neurol. 2002 Dec;15(6):663-9 [12447103.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):499-509 [15509483.001]
  • [Cites] J Neurosci. 2000 Nov 1;20(21):7994-8004 [11050120.001]
  • [Cites] J Invest Surg. 2004 Sep-Oct;17(5):283-9 [15385261.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):477-85 [11836272.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):495-506 [12057095.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):377-84 [15015671.001]
  • (PMID = 16840829.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Somatomedins; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; 9002-71-5 / Thyrotropin; 9002-72-6 / Growth Hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; 94ZLA3W45F / Arginine; Q51BO43MG4 / Thyroxine; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


30. Hohenstein C, Herdtle S: Unexpected death from a colloid cyst. Int J Emerg Med; 2010;3(1):65-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Colloid cysts are usually benign brain tumors, which rarely cause acute neurological deterioration with sudden death due to an acute increase of intracranial pressure.
  • CONCLUSION: Subtle distinctions between symptoms due to intracranial hypertension, which typically cause headache and vomiting, and true gastroenteritis are discussed as well as the pathophysiology of neurogenic pulmonary edema and the origin of cerebral-triggered cardiac dysrhythmias.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1996 Feb;38(2):392-5 [8869070.001]
  • [Cites] Ann Emerg Med. 1997 Apr;29(4):524-8 [9095015.001]
  • [Cites] Clin Neurol Neurosurg. 2002 Sep;104(4):367-70 [12140107.001]
  • [Cites] Childs Nerv Syst. 2006 Mar;22(3):305-9 [16180045.001]
  • [Cites] J Clin Neurosci. 1995 Oct;2(4):307-11 [18638833.001]
  • [Cites] Acta Anaesthesiol Scand. 2007 Apr;51(4):447-55 [17378783.001]
  • [Cites] Physiol Res. 2008;57(4):499-506 [18052674.001]
  • [Cites] Am J Forensic Med Pathol. 2008 Jun;29(2):170-2 [18520488.001]
  • [Cites] Pediatr Cardiol. 2006 Mar-Apr;27(2):286-8 [16463127.001]
  • (PMID = 20414387.001).
  • [ISSN] 1865-1380
  • [Journal-full-title] International journal of emergency medicine
  • [ISO-abbreviation] Int J Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2850975
  • [Keywords] NOTNLM ; Cardiopulmonary complication / Colloid cyst / Unexpected death
  •  go-up   go-down


31. Yang Y, Shao N, Luo G, Li L, Nilsson-Ehle P, Xu N: Relationship between PTEN gene expression and differentiation of human glioma. Scand J Clin Lab Invest; 2006;66(6):469-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor-adjacent normal tissues and benign brain tumors were used as controls.
  • RESULTS: PTEN mRNA levels were significantly lower in the glioma tissues than in the benign brain tumors and tumor-adjacent normal tissues, whereas there were no statistical differences between benign brain tumor and the tumor-adjacent normal tissues.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Glioma / genetics. Glioma / pathology. PTEN Phosphohydrolase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Astrocytoma / pathology. Child. Female. Gene Expression. Genes, Tumor Suppressor. Glioblastoma / genetics. Glioblastoma / pathology. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Humans. Male. Meningioma / genetics. Meningioma / pathology. Middle Aged. Mutation. Neuroma, Acoustic / genetics. Neuroma, Acoustic / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000554.001).
  • [ISSN] 0036-5513
  • [Journal-full-title] Scandinavian journal of clinical and laboratory investigation
  • [ISO-abbreviation] Scand. J. Clin. Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


32. Boviatsis EJ, Bouras TI, Kouyialis AT, Themistocleous MS, Sakas DE: Impact of age on complications and outcome in meningioma surgery. Surg Neurol; 2007 Oct;68(4):407-11; discussion 411
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Surgery for benign brain tumors in elderly patients without severe general health problems is an acceptable practice, as results are comparable with the ones of younger patients.
  • Tumor removal rate was not significantly different in the 2 groups.
  • Regarding each complication, postoperative hematoma, infections, and deep vein thrombosis were more frequent in elderly patients, presenting various degrees of statistical significance, whereas postoperative brain edema, hydrocephalus, and cardiorespiratory incidents presented no statistically significant difference.
  • [MeSH-major] Meningioma / surgery. Postoperative Complications / epidemiology. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cerebral Hemorrhage / etiology. Craniotomy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Nervous System Diseases / epidemiology. Neurosurgical Procedures. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17586023.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Scoles DR: The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta; 2008 Jan;1785(1):32-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neurofibromatosis 2 (NF2) tumor suppressor protein merlin is commonly mutated in human benign brain tumors.
  • Review of all of the merlin interacting proteins and functional consequences of losses of these interactions reveals multiple merlin actions in PI3-kinase, MAP kinase and small GTPase signaling pathways that might be targeted to inhibit the proliferation of NF2 tumors.
  • [MeSH-minor] Animals. Binding Sites. Cytoskeletal Proteins / metabolism. Humans. Models, Biological. Protein Folding. Tumor Suppressor Proteins / administration & dosage. Tumor Suppressor Proteins / metabolism


34. Gokce M: Analysis of isolated cranial nerve manifestations in patients with cancer. J Clin Neurosci; 2005 Nov;12(8):882-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a prospective study over a 16 month period, 20 of 242 patients presented with isolated CN manifestations, and were assessed for the following: primary site; CN symptoms and signs; length of time between primary diagnosis and neurological involvement; and survival following the neurological diagnosis.
  • They included meningeal carcinomatosis (10/16), brain stem metastases (3/16), primary brain astrocytomas (1/16), and metastases out of the central nervous system (2/16).
  • Although most of the isolated CN manifestations were due to systemic metastasis, in particular to the meninges, up to 20% were related to benign conditions.
  • [MeSH-major] Cranial Nerve Diseases / etiology. Neoplasms / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Meningeal Neoplasms / secondary. Middle Aged. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16326269.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


35. Kaynar MY, Sanus GZ, Hnimoglu H, Kacira T, Kemerdere R, Atukeren P, Gumustas K, Canbaz B, Tanriverdi T: Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma. J Clin Neurosci; 2008 Sep;15(9):1036-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma.
  • There was no statistically significant difference between the two types of tumor (p=0.264).
  • These findings indicate that HIF-1alpha is elevated in both TM and GBM, suggesting that although hypoxia is one of the most important and powerful stimuli for HIF-1alpha elevation and consequently angiogenesis, other mechanisms may play roles in HIF-1alpha stimulation in benign brain tumors such as TM.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Anoxia / diagnosis. Anoxia / metabolism. Anoxia / physiopathology. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cell Hypoxia / physiology. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neovascularization, Pathologic / etiology. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / physiopathology. Predictive Value of Tests. Up-Regulation / physiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18621534.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  •  go-up   go-down


36. Yao Y, Tang X, Li S, Mao Y, Zhou L: Brain tumor stem cells: view from cell proliferation. Surg Neurol; 2009 Mar;71(3):274-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor stem cells: view from cell proliferation.
  • A small population of TSCs, which form neurospheres and possess the capacity for self-renewal, has been recently identified in adult and pediatric brain tumors.
  • They differentiate into phenotypically diverse populations, including neuronal, astrocytic, and oligodendroglial cells in vitro and recapitulate original tumors in vivo.
  • The understanding of brain TSCs has been greatly advanced by the knowledge of cell proliferation, which contributes to initiate and sustain the malignant phenotype.
  • In this article, the authors summarized the evidence of the presence of TSCs in human brain tumors and emphasized the significance of the proliferative status of TSCs.
  • Finally, the preliminary evidence that TSCs in malignant brain tumors have more proliferative capacity than stem/progenitor cells in benign brain tumors was discussed.
  • [MeSH-major] Adult Stem Cells / pathology. Brain Neoplasms / pathology. Neoplastic Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249579.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


37. Liu AK, Bagrosky B, Fenton LZ, Gaspar LE, Handler MH, McNatt SA, Foreman NK: Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy. Pediatr Blood Cancer; 2009 Feb;52(2):227-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Craniopharyngioma is a benign brain tumor that can be treated with some combination of surgery, intracystic chemotherapy and radiation therapy.
  • One had bilateral temporal cavernomas, one had moyamoya syndrome, one had an aneurysm of the internal carotid artery and three children had decreases in the caliber of the carotid or cerebral arteries, but were asymptomatic.

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Vascular Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18937328.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin
  •  go-up   go-down


38. Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, Bürki N, Diesch C, Holzgreve W, Zhong XY: Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer; 2009;8:105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors.
  • METHODS: Using multiplex real-time PCR we investigated the levels of ccf nDNA and mtDNA in plasma samples from patients with malignant and benign breast tumors, and from healthy controls.
  • RESULTS: While the levels of ccf nDNA in the cancer group were significantly higher in comparison with the benign tumor group (P < 0.001) and the healthy control group (P < 0.001), the level of ccf mtDNA was found to be significantly lower in the two tumor-groups (benign: P < 0.001; malignant: P = 0.022).
  • The level of ccf nDNA was also associated with tumor-size (<2 cm vs. >2 cm<5 cm; 2250 vs. 6658; Mann-Whitney-U-Test: P = 0.034).
  • Using ROC curve analysis, we were able to distinguish between the breast cancer cases and the healthy controls using ccf nDNA as marker (cut-off: 1866 GE/ml; sensitivity: 81%; specificity: 69%; P < 0.001) and between the tumor group and the healthy controls using ccf mtDNA as marker (cut-off: 463282 GE/ml; sensitivity: 53%; specificity: 87%; P < 0.001).
  • CONCLUSION: Our data suggests that nuclear and mitochondrial ccf DNA have potential as biomarkers in breast tumor management.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Cell Nucleus / genetics. DNA, Mitochondrial / blood
  • [MeSH-minor] Case-Control Studies. Cell-Free System. Cohort Studies. Diagnosis, Differential. Female. Health. Humans. Lymph Nodes / pathology. Neoplasm Metastasis. ROC Curve. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2006 Aug;24(8):905-8 [16900126.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):629-38 [16568452.001]
  • [Cites] BMC Cancer. 2006;6:269 [17116247.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2631-9 [17182988.001]
  • [Cites] Mitochondrion. 2007 Feb-Apr;7(1-2):157-63 [17280876.001]
  • [Cites] Mitochondrion. 2007 Feb-Apr;7(1-2):53-7 [17320491.001]
  • [Cites] Acta Paediatr. 2007 May;96(5):644-7 [17376185.001]
  • [Cites] Int J Biol Markers. 2007 Apr-Jun;22(2):95-9 [17549664.001]
  • [Cites] Arch Gynecol Obstet. 2007 Oct;276(4):327-31 [17431649.001]
  • [Cites] Prostate. 2008 Mar 1;68(4):408-17 [18196528.001]
  • [Cites] Clin Chem Lab Med. 2008;46(3):311-7 [18254709.001]
  • [Cites] JAMA. 2008 May 14;299(18):2151-63 [18477782.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):921-5 [18507037.001]
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Jun;16(3):699-703 [18549658.001]
  • [Cites] Int J Biol Markers. 2008 Apr-Jun;23(2):69-73 [18629778.001]
  • [Cites] DNA Cell Biol. 2008 Aug;27(8):415-21 [18694299.001]
  • [Cites] Nat Med. 2008 Sep;14(9):985-90 [18670422.001]
  • [Cites] Obstet Gynecol. 2008 Oct;112(4):843-50 [18827127.001]
  • [Cites] Ann N Y Acad Sci. 2008 Aug;1137:175-9 [18837944.001]
  • [Cites] Cytokine. 2008 Oct;44(1):65-9 [18691902.001]
  • [Cites] Expert Rev Neurother. 2008 Dec;8(12):1841-52 [19086880.001]
  • [Cites] Neuroimage. 2009 Jun;46(2):394-410 [19236926.001]
  • [Cites] Clin Chem. 2000 Dec;46(12):1903-6 [11106320.001]
  • [Cites] Lancet. 2001 Jan 27;357(9252):310-1 [11214156.001]
  • [Cites] Swiss Med Wkly. 2001 Feb 10;131(5-6):70-4 [11383228.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;945:138-40 [11708467.001]
  • [Cites] Clin Chim Acta. 2002 Jul;321(1-2):77-87 [12031596.001]
  • [Cites] Int J Gynaecol Obstet. 1995 Feb;48(2):187-92 [7540567.001]
  • [Cites] Lab Invest. 1996 Mar;74(3):592-9 [8600309.001]
  • [Cites] Brain Res Mol Brain Res. 1997 Dec 15;52(2):284-9 [9495550.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):920-4 [15856456.001]
  • [Cites] Tumour Biol. 2005 Nov-Dec;26(6):281-93 [16254457.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1564-9 [16533782.001]
  • [Cites] Prenat Diagn. 2006 Apr;26(4):362-8 [16566058.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1087-91 [17047655.001]
  • (PMID = 19922604.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Mitochondrial; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2780981
  •  go-up   go-down


39. Aguirre-Quezada DE, Martínez-Anda JJ, Aguilar-Ayala EL, Chávez-Macías L, Olvera-Rabiela JE: [Intracranial and intramedullary peripheral nerve sheath tumours. Case reports from 20 autopsies]. Rev Neurol; 2006 Aug 16-31;43(4):197-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumores de vaina de nervio periférico intracraneales e intrarraquídeos. Informe de 20 casos de autopsia.
  • INTRODUCTION: Tumors arising from the sheath of peripheral nerves, both intracranial and intraspinal, are uncommon and are sometimes of difficult clinical diagnosis, especially when they occur in unusual sites.
  • Histological malignancy of this neoplasm is rare.
  • MATERIALS AND METHODS: The clinical and pathological findings of 20 autopsy cases of intracranial and intraspinal peripheral nerve tumors are analyzed.
  • 14 cases were surgically treated and the causes of death were ischemic lesions due to the large size of the tumors.
  • The correct clinical diagnosis was made in 14 patients.
  • The importance of early detection on intracranial and intraspinal peripheral tumors is paramount, since the large size of these histologically benign neoplasms makes them biologically malignant.
  • [MeSH-major] Brain Neoplasms / pathology. Cranial Nerve Neoplasms / pathology. Nerve Sheath Neoplasms / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Autopsy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neurilemmoma / pathology. Neurofibromatosis 1 / pathology. Neurofibromatosis 2 / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883507.001).
  • [ISSN] 0210-0010
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


40. Qaddoumi I, Ellison DW, Morris EB, Broniscer A, Boop F, Merchant T, Palmer SL, Gajjar A: Dysembryoplastic neuroepithelial tumors and cognitive outcome: cure at a price? Cancer; 2010 Dec 1;116(23):5461-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysembryoplastic neuroepithelial tumors and cognitive outcome: cure at a price?
  • BACKGROUND: Dysembryoplastic neuroepithelial tumors (DNETs) are benign glioneuronal tumors that occur in children.
  • These tumors are characterized by seizures, lack of neurologic deficits, and a seemingly benign course after resection.
  • RESULTS: The patient cohort included 8 boys and 3 girls (median age at diagnosis, 10 years); all patients presented with seizures: 4 complex partial, 3 generalized tonic-clonic, 2 absence, 1 partial simple, and 1 not classified.
  • Of the 11 patients, 1 died of cardiac fibrosis, and tumors recurred or progressed in 4 (36%) patients.
  • CONCLUSIONS: The high recurrence and progression rates of DNETs and the high rate of abnormal neurocognitive test results noted in the current study highlight the need for regular follow-up and appropriate academic counseling of children with these tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Cognition Disorders / etiology. Neoplasms, Neuroepithelial / diagnosis. Neoplasms, Neuroepithelial / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Craniotomy / adverse effects. Educational Status. Female. Humans. Intelligence Tests. Male. Neoplasm Recurrence, Local. Seizures / diagnosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • [Cites] Brain. 2000 Dec;123 Pt 12:2445-66 [11099447.001]
  • [Cites] Epilepsy Behav. 2009 Oct;16(2):341-4 [19751992.001]
  • [Cites] J Neuroradiol. 2001 Dec;28(4):230-40 [11924137.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 May;24(5):829-34 [12748079.001]
  • [Cites] Neurology. 2004 Jun 22;62(12):2270-6 [15210893.001]
  • [Cites] Lancet Neurol. 2004 Nov;3(11):663-72 [15488459.001]
  • [Cites] Neurosurgery. 1988 Nov;23(5):545-56 [3143922.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Sep-Oct;13(5):1319-25 [1414821.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):283-95 [8293188.001]
  • [Cites] Brain. 1994 Jun;117 ( Pt 3):461-75 [8032857.001]
  • [Cites] Histopathology. 1999 Apr;34(4):342-56 [10231402.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):267-80 [10359147.001]
  • [Cites] J Child Neurol. 2005 Apr;20(4):377-84 [15921242.001]
  • [Cites] Neurosurg Focus. 2005 Jun 15;18(6A):E5 [16048291.001]
  • [Cites] J Neurosurg. 2006 Jan;104(1):62-9 [16509148.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Br J Neurosurg. 2007 Dec;21(6):539-49 [18071981.001]
  • [Cites] J Neurosurg Pediatr. 2008 Mar;1(3):206-10 [18352764.001]
  • [Cites] Pediatr Neurosurg. 2008;44(4):333-6 [18552517.001]
  • [Cites] Eur J Oncol Nurs. 2009 Jul;13(3):171-8 [19019733.001]
  • [Cites] J Neurooncol. 2009 Sep;94(2):283-92 [19267228.001]
  • [Cites] Neurology. 2009 Aug 18;73(7):526-34 [19675309.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Apr;70(4):450-8 [11254766.001]
  • (PMID = 20672357.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS218175; NLM/ PMC3556450
  •  go-up   go-down


41. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: In March 1996, a 37 year-old male underwent surgical resection for a left occipital intraventricular benign meningioma (WHO I).
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • Workup studies failed to reveal any primary tumor.
  • In May 2004 the patient was admitted to our department and a new transpedicular biopsy confirmed the diagnosis.
  • Definite pathology: benign meningioma (WHO I).
  • DISCUSSION: Distant metastases from intracranial meningiomas are rare entities, arising from benign lesions in, at least, 60% of cases.
  • Enam et al proposed a specific pathological score to differentiate benign, atypic and malignant meningiomas.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.
  • Hematogenous (especially venous; Batson's perivertebral plexus), linfatic and cerebrospinal fluid are the main routes involved in the spreading of the tumor.
  • [MeSH-major] Meningioma / pathology. Orthopedic Procedures / methods. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery. Thoracic Vertebrae
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Review Literature as Topic

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


42. Zekri JM, Manifold IH, Wadsley JC: Metastatic struma ovarii: late presentation, unusual features and multiple radioactive iodine treatments. Clin Oncol (R Coll Radiol); 2006 Dec;18(10):768-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic malignant struma ovarii is rare and there is a lack of agreement on the criteria of diagnosis and the lines of management.
  • Here we describe a patient with struma ovarii that was initially diagnosed as benign and presented 10 years later with distant metastases.
  • The case was associated with a number of unusual features and challenging management issues, such as a delayed diagnosis of recurrence, functioning metastases with treatment consequences, tumour lysis-induced thyrotoxicosis and cerebrospinal fluid rhinorrhea.
  • The diagnosis and management of struma ovarii should be led by an expert multidisciplinary team.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / radiotherapy. Struma Ovarii / diagnosis. Struma Ovarii / radiotherapy
  • [MeSH-minor] Adult. Brain Neoplasms / pathology. Brain Neoplasms / secondary. Diagnosis, Differential. Female. Humans. Iodine Radioisotopes / therapeutic use. Neoplasm Metastasis. Ovarian Follicle / pathology. Thyroglobulin / metabolism. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / secondary. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168212.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


43. McCall T, Chin SS, Salzman KL, Fults DW: Tuberous sclerosis: a syndrome of incomplete tumor suppression. Neurosurg Focus; 2006;20(1):E3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberous sclerosis: a syndrome of incomplete tumor suppression.
  • The latter is a benign brain tumor of mixed neuronal and glial origin.
  • [MeSH-major] Hamartoma / complications. Tuberous Sclerosis / etiology. Tuberous Sclerosis / genetics. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Animals. Brain Neoplasms / complications. Brain Neoplasms / genetics. Humans. Models, Biological

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16459993.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein
  • [Number-of-references] 92
  •  go-up   go-down


44. Hourani R, Horská A, Albayram S, Brant LJ, Melhem E, Cohen KJ, Burger PC, Weingart JD, Carson B, Wharam MD, Barker PB: Proton magnetic resonance spectroscopic imaging to differentiate between nonneoplastic lesions and brain tumors in children. J Magn Reson Imaging; 2006 Feb;23(2):99-107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopic imaging to differentiate between nonneoplastic lesions and brain tumors in children.
  • PURPOSE: To investigate whether in vivo proton magnetic resonance spectroscopic imaging (MRSI) can differentiate between 1) tumors and nonneoplastic brain lesions, and 2) high- and low-grade tumors in children.
  • MATERIALS AND METHODS: Thirty-two children (20 males and 12 females, mean age = 10 +/- 5 years) with primary brain lesions were evaluated retrospectively.
  • Nineteen patients had a neuropathologically confirmed brain tumor, and 13 patients had a benign lesion.
  • RESULTS: Considering all possible combinations of metabolite ratios, the best discriminant function to differentiate between nonneoplastic lesions and brain tumors was found to include only the ratio of Cho/Cr (Wilks' lambda, P = 0.012; 78.1% of original grouped cases correctly classified).
  • The best discriminant function to differentiate between high- and low-grade tumors included the ratios of NAA/Cr and Cho(norm) (Wilks' lambda, P = 0.001; 89.5% of original grouped cases correctly classified).
  • Cr levels in low-grade tumors were slightly lower than or comparable to control regions and ranged from 53% to 165% of the control values in high-grade tumors.
  • CONCLUSION: Proton MRSI may have a promising role in differentiating pediatric brain lesions, and an important diagnostic value, particularly for inoperable or inaccessible lesions.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Germinoma / diagnosis. Glioma / diagnosis. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adolescent. Biopsy, Needle. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2005 Wiley-Liss, Inc.
  • (PMID = 16374884.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS042851; United States / NCRR NIH HHS / RR / P41RR15241
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


45. Rogers L, Gilbert M, Vogelbaum MA: Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol; 2010 Sep;99(3):393-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical (WHO grade II) meningiomas occupy an intermediate risk group between benign (WHO grade I) and anaplastic (WHO grade III) meningiomas.
  • We will discuss the definition, diagnosis, and treatment of patients with atypical meningioma; review the current phase II cooperative trials; and draw attention to some questions timely for pre-clinical and clinical research.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Humans. Neoplasm Staging. Prognosis. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2009 Jan;64(1):56-60; discussion 60 [19145156.001]
  • [Cites] Radiology. 1987 Aug;164(2):521-6 [3496626.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] Clin Nucl Med. 2005 Nov;30(11):717-20 [16237292.001]
  • [Cites] J Neurooncol. 2007 Aug;84(1):41-7 [17361335.001]
  • [Cites] Neurol Res. 1999 Oct;21(7):640-4 [10555183.001]
  • [Cites] Acta Neurochir (Wien). 1995;135(3-4):171-8 [8748810.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):386-408 [12946028.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):728-34 [12640680.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Eur J Radiol. 2006 Oct;60(1):48-55 [16844335.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):384-90 [10470811.001]
  • [Cites] Neurol Res. 2007 Jan;29(1):43-6 [17427274.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Jun;29(6):1147-52 [18356472.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Clin Radiol. 2007 Feb;62(2):109-19 [17207692.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):99-105 [11163502.001]
  • [Cites] Neuroradiology. 1990;32(6):467-73 [2287373.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]
  • [Cites] Neurosurgery. 1993 Sep;33(3):394-9; discussion 399 [8413869.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63 [17379447.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):817-22 [8598358.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17 (2):345-53 [8938309.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Neurosurgery. 2009 Feb;64(2 Suppl):A7-13 [19165077.001]
  • [Cites] Clin Nucl Med. 2009 Jan;34(1):7-10 [19092373.001]
  • [Cites] J Clin Neurosci. 2003 Sep;10(5):589-93 [12948465.001]
  • [Cites] Neuroradiology. 2006 Aug;48(8):513-20 [16786348.001]
  • [Cites] J Neurosurg. 1999 Dec;91(6):928-34 [10584837.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] Osaka City Med J. 1997 Dec;43(2):209-23 [9540343.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Oct;29(9):1630-5 [18583409.001]
  • [Cites] Chin Med J (Engl). 2008 Dec 5;121(23):2415-9 [19102960.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1 [12823874.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:283-6 [15662826.001]
  • [Cites] Clin Imaging. 2008 Jan-Feb;32(1):22-7 [18164390.001]
  • [Cites] Ann N Y Acad Sci. 1982;381:6-16 [6953802.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Oct;36(10 ):1574-82 [19377904.001]
  • [Cites] Strahlenther Onkol. 1998 Dec;174(12):624-8 [9879349.001]
  • [Cites] Surg Neurol. 2004 Feb;61(2):171-3 [14751635.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):293-6; discussion 296-7 [16953450.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):70-4 [15685038.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Neurosurgery. 2010 Apr;66(4):661-8; discussion 668-9 [20305491.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] Neurosurgery. 2008 May;62(5 Suppl):A19-27; discussion A27-8 [18580776.001]
  • [Cites] Eur Radiol. 2003 Mar;13(3):582-91 [12594562.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] J Neurooncol. 1998 Aug;39(1):65-70 [9760071.001]
  • [Cites] Curr Opin Neurol. 2010 Dec;23(6):563-70 [20885321.001]
  • [Cites] Radiologia. 2009 Jul-Aug;51(4):411-9 [19552929.001]
  • [Cites] J Neurosurg. 1996 Jun;84(6):946-50 [8847588.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:108-11 [8738510.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] J Nucl Med. 1997 Jan;38(1):26-30 [8998144.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Jan;22(1):65-72 [11158890.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E3 [18447742.001]
  • [Cites] Radiology. 2005 Jun;235(3):985-91 [15833979.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E4 [17961041.001]
  • [Cites] J Neuroradiol. 1992;19(1):49-62 [1564530.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):399-406 [19203844.001]
  • (PMID = 20740303.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


46. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL: Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol; 2008 Jan 1;26(1):96-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We tested the hypothesis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions.
  • ATIII RNA transcripts were identified within CNS lymphomas, and ATIII protein was localized selectively to tumor neovasculature.
  • We propose that the discovery of CSF protein biomarkers will facilitate early and noninvasive diagnosis in patients with lesions not amenable to brain biopsy, as well as provide improved surrogates of prognosis and treatment response in CNS lymphoma and brain metastasis.
  • [MeSH-major] Biomarkers, Tumor / cerebrospinal fluid. Brain Neoplasms / cerebrospinal fluid. Lymphoma / cerebrospinal fluid. Neoplasm Proteins / cerebrospinal fluid
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antithrombin III / genetics. Antithrombin III / metabolism. Case-Control Studies. Chromatography, Liquid. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoblotting. Immunoenzyme Techniques. Leukemia, Myeloid / cerebrospinal fluid. Leukemia, Myeloid / pathology. Lymphoma, B-Cell / cerebrospinal fluid. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / cerebrospinal fluid. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / cerebrospinal fluid. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / cerebrospinal fluid. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Proteomics. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3575-82 [15284095.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):705-17, vii [16083831.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1341-9 [15970584.001]
  • [Cites] Dis Markers. 2006;22(1-2):3-26 [16410649.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37302-10 [17040907.001]
  • [Cites] Expert Rev Mol Med. 2006;8(31):1-19 [17156576.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Anal Chem. 2003 Sep 15;75(18):4818-26 [14674459.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2053-63 [12466122.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):641-8 [11148663.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2922-7 [15131026.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1):72-5 [17236490.001]
  • [CommentIn] J Clin Oncol. 2009 May 1;27(13):2302-3; author reply 2303-4 [19332721.001]
  • (PMID = 18056677.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA100291
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 9000-94-6 / Antithrombin III
  • [Other-IDs] NLM/ NIHMS612770; NLM/ PMC4134101
  •  go-up   go-down


47. Regelsberger J, Hagel C, Emami P, Ries T, Heese O, Westphal M: Secretory meningiomas: a benign subgroup causing life-threatening complications. Neuro Oncol; 2009 Dec;11(6):819-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretory meningiomas: a benign subgroup causing life-threatening complications.
  • While meningiomas are known as slow-growing extracerebral neoplasms, the subgroup of secretory meningiomas with histologically benign characteristics tend to cause disproportional peritumoral edema, frequently leading to severe medical and neurological complications in postoperative management.
  • Among 1,484 meningiomas that were resected at our institution between 1990 and 2007, 44 (3%) patients were found to have the histological diagnosis of a secretory meningioma.
  • The clinical course, radiological appearance, and histopathological features were retrospectively analyzed to examine the specifics of these benign lesions.
  • A severe, nearly hemispheric perifocal edema disproportional to tumor size was seen on preoperative MR imaging in 18 (41%) patients.
  • An association between the extent of brain edema and number of periodic acid Schiff-positive pseudopsammomas was found (p < 0.02).
  • Mean MIB-1 (Ki-67 antigen) proliferation index was 3.0% (range, 0%-17%) and did not correlate with edema or tumor recurrence.
  • [MeSH-major] Brain Edema / etiology. Meningeal Neoplasms / complications. Meningeal Neoplasms / metabolism. Meningioma / complications. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / metabolism. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Keratins / metabolism. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / metabolism. Neoplasm Staging. Prognosis. Retrospective Studies. Tomography, X-Ray Computed

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Clin Path. 1999 Jul;3(3):47-53 [10655573.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):297-301; discussion 301-2 [11220371.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:19-21 [11386820.001]
  • [Cites] J Clin Neurosci. 2001 Jul;8(4):335-9 [11437574.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):765-72 [11857311.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):590-8 [12152157.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):353-7 [17721284.001]
  • [Cites] Am J Surg Pathol. 1986 Feb;10(2):102-11 [2420220.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 1989 Dec;18(4):287-9 [2636960.001]
  • [Cites] Histopathology. 1992 Nov;21(5):475-7 [1452131.001]
  • [Cites] Cancer. 1997 May 15;79(10):2003-15 [9149029.001]
  • [Cites] Neurosurg Rev. 2006 Jan;29(1):41-8 [16010579.001]
  • [Cites] Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 May;37(3):488-91 [16761441.001]
  • [Cites] J Neurooncol. 2003 May;62(3):233-41 [12777074.001]
  • (PMID = 19066343.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Ki-67 Antigen; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC2802401
  •  go-up   go-down


48. Ali Y, Rahme R, Moussa R, Abadjian G, Menassa-Moussa L, Samaha E: Multifocal meningeal melanocytoma: a new pathological entity or the result of leptomeningeal seeding? J Neurosurg; 2009 Sep;111(3):488-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningeal melanocytoma is a rare benign CNS tumor derived from the leptomeningeal melanocytes.
  • Although unusual, malignant transformation with leptomeningeal seeding into the brain or spinal cord may occur years after the initial diagnosis.
  • The authors report a unique case of multifocal benign meningeal melanocytoma involving both cerebellopontine angles and the thoracic spinal cord, with associated diffuse leptomeningeal hyperpigmentation.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellopontine Angle. Melanocytes / pathology. Melanoma / pathology. Meningeal Neoplasms / pathology. Neoplasm Seeding. Spinal Cord Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361258.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Badr El-Din NK, Settin A, Ali N, Abdel-Hady el-SK, Salem FK: Cytokine gene polymorphisms in egyptian cases with brain tumors. J Egypt Natl Canc Inst; 2009 Jun;21(2):101-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine gene polymorphisms in egyptian cases with brain tumors.
  • BACKGROUND: Cytokines are proposed to play important roles in brain tumor biology as well as neurodegeneration or impaired neuronal function.
  • OBJECTIVES: This work aimed to check the association of polymorphisms of cytokine genes in Egyptian cases with brain tumors.
  • METHODS: This work included 45 cases affected by brain tumors diagnosed as 24 benign and 21 malignant.
  • RESULTS: Cases affected with benign brain tumors showed a significant higher frequency of IL-10-1082 A/A [odds ratio (OR=8.0), p<0.001] and IL-6-174 C/C (OR=6.3, p=0.002) homozygous genotypes as compared to controls.
  • CONCLUSIONS: Cytokine gene polymorphisms showed a pattern of association with brain tumors which may have potential impact on family counseling and disease management.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Cytokines / genetics. Polymorphism, Genetic / genetics
  • [MeSH-minor] Case-Control Studies. DNA / genetics. Egypt. Female. Genotype. Humans. Interleukin 1 Receptor Antagonist Protein / genetics. Interleukin-10 / genetics. Interleukin-6 / genetics. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Tumor Necrosis Factor-alpha / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21057561.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / Interleukin 1 Receptor Antagonist Protein; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 9007-49-2 / DNA
  •  go-up   go-down


50. Bianco Ade M, Madeira LV, Rosemberg S, Shibata MK: Cortical seeding of a craniopharyngioma after craniotomy: Case report. Surg Neurol; 2006 Oct;66(4):437-40; discussion 440
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A left frontotemporal craniotomy was done with subtotal resection of the tumor because it was strongly adhered to the optic chiasm.
  • Histopathology confirmed the diagnosis of craniopharyngioma.
  • Magnetic resonance imaging revealed a contrast-enhancing tumor with cystic and solid components on the left temporal lobe cortex.
  • The primary tumor bed was intact.
  • The patient was reoperated, and the temporal lobe tumor was totally removed.
  • CONCLUSIONS: Although craniopharyngiomas exhibit a benign histopathologic pattern, a total resection combined with careful inspection and irrigation of the surgical field is the optimal treatment for preventing local and ectopic recurrences.
  • [MeSH-major] Brain Neoplasms / secondary. Craniopharyngioma / secondary. Neoplasm Seeding. Pituitary Neoplasms / pathology. Temporal Lobe / pathology
  • [MeSH-minor] Adult. Craniotomy. Female. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Neurosurgical Procedures / methods. Neurosurgical Procedures / standards. Optic Chiasm / pathology. Optic Chiasm / physiopathology. Seizures / etiology. Seizures / physiopathology. Treatment Outcome. Vision, Low / etiology. Vision, Low / physiopathology


51. Chen CL, Shen CC, Wang J, Lu CH, Lee HT: Central neurocytoma: a clinical, radiological and pathological study of nine cases. Clin Neurol Neurosurg; 2008 Feb;110(2):129-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Central neurocytoma is a rare intraventricular brain tumor that affects young adults and presents with increased intracranial pressure secondary to obstructive hydrocephalus.
  • In this report, we describe the diagnosis and treatment of central neurocytoma in a series of patients at our institution.
  • PATIENTS AND METHODS: Our series of nine patients (M:F=2:7, mean age, 28.2 years) with ventricular tumors showed typical radiological, histologic and immunohistochemical features of central neurocytoma.
  • Most patients received craniotomy with removal of the tumor through transcallosal or transcortical approach.
  • CONCLUSION: Although central neurocytoma is generally a benign neoplasm, some variant forms of recurrence are also present.
  • Recurrent tumors are often local and the patients seem to recover well after a second resection followed by radiotherapy.
  • Histologic features such as tumor proliferation (MIB-1 labeling index), vascular proliferation, and synaptophysin expression are often prominent in the recurrent tumor.
  • We recommend that these histologic features be considered for tumor recurrence during treatment and follow-up of these patients.

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 1;88(1):169-74 [10618620.001]
  • [Cites] J Neurosurg. 2007 Jul;107(1):7-12 [17639866.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1111-20 [10964342.001]
  • [Cites] Surg Neurol. 2001 Feb;55(2):74-8 [11301084.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):879-82 [11702880.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1365-7 [12015858.001]
  • [Cites] Br J Neurosurg. 2002 Apr;16(2):126-32 [12046730.001]
  • [Cites] Neurology. 2002 Oct 22;59(8):1268-70 [12391364.001]
  • [Cites] J Magn Reson Imaging. 2003 Feb;17(2):256-60 [12541233.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):255-9 [12675319.001]
  • [Cites] Surg Neurol. 2003 Dec;60(6):560-5 [14670681.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):377-84 [15015671.001]
  • [Cites] Acta Neuropathol. 1982;56(2):151-6 [7064664.001]
  • [Cites] Acta Neuropathol. 1990;79(5):473-9 [2109481.001]
  • [Cites] J Neurooncol. 1990 Dec;9(3):231-8 [2086738.001]
  • [Cites] Lab Invest. 1991 Apr;64(4):585-91 [1901927.001]
  • [Cites] Neuroradiology. 1991;33(2):143-8 [2046899.001]
  • [Cites] J Neurosurg. 1992 Jan;76(1):32-7 [1727166.001]
  • [Cites] Radiology. 1992 Mar;182(3):787-92 [1535895.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1350-5 [8339224.001]
  • [Cites] Acta Radiol. 1993 Sep;34(5):520-6 [8369193.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):297-306 [8293189.001]
  • [Cites] Surg Neurol. 1994 Oct;42(4):335-9 [7974132.001]
  • [Cites] Clin Neurol Neurosurg. 1995 Aug;97(3):219-28 [7586853.001]
  • [Cites] Surg Neurol. 1996 Jan;45(1):49-56 [9190699.001]
  • [Cites] J Neurosurg. 1996 May;84(5):742-7 [8622146.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):790-5 [9024717.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):547-52 [9046315.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):551-6 [9143268.001]
  • [Cites] Cancer. 1997 May 15;79(10):1995-2002 [9149028.001]
  • [Cites] J Neurooncol. 1997 Sep;34(3):279-83 [9258819.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):197-204 [9457271.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):155-9 [10393370.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):506-9 [10470830.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):53-9 [15719276.001]
  • [Cites] Neurosurg Rev. 2005 Apr;28(2):96-103 [15580370.001]
  • [Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):683-8 [16163043.001]
  • [Cites] Strahlenther Onkol. 2006 Jul;182(7):415-8 [16826361.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):286-92; discussion 292 [16604374.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):270-85; discussion 285 [16941163.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1145-54 [17187939.001]
  • [Cites] Neuroradiology. 2007 Jul;49(7):551-4 [17364196.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):329-33; discussion 333-4 [10690721.001]
  • (PMID = 18022760.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS039918-03; United States / NINDS NIH HHS / NS / R01 NS039918-02; United States / NINDS NIH HHS / NS / NS039918-02; United States / NINDS NIH HHS / NS / R01 NS039918-01; United States / NINDS NIH HHS / NS / NS039918-03; United States / NINDS NIH HHS / NS / NS039918-01
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS39918; NLM/ PMC2702989
  •  go-up   go-down


52. Jagannathan J, Kanter AS, Sheehan JP, Jane JA Jr, Laws ER Jr: Benign brain tumors: sellar/parasellar tumors. Neurol Clin; 2007 Nov;25(4):1231-49, xi
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign brain tumors: sellar/parasellar tumors.
  • Neoplasms of the sellar region include pituitary adenomas, craniopharyngiomas, Rathke's cleft cysts, and, less commonly, meningiomas, germinomas, and hamartomas.
  • The diagnosis of sellar lesions involves a multidisciplinary effort; detailed endocrinologic, ophthalmologic, and neurologic tests are critical.
  • The management of pituitary tumors varies.
  • For most tumors, transsphenoidal resection remains the mainstay of treatment.
  • [MeSH-major] Brain Neoplasms / pathology. Pituitary Neoplasms / pathology. Sella Turcica / pathology
  • [MeSH-minor] Acromegaly / diagnosis. Chemotherapy, Adjuvant. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Pituitary ACTH Hypersecretion / diagnosis. Pituitary ACTH Hypersecretion / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964033.001).
  • [ISSN] 0733-8619
  • [Journal-full-title] Neurologic clinics
  • [ISO-abbreviation] Neurol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  •  go-up   go-down


53. Wu C, Yen YS, Ho DM, Guo W: Primary neurocytoma in the spinal cord. A case report. Neuroradiol J; 2006 Nov 30;19(5):672-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central neurocytoma is defined as an intraventricular benign brain tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24351271.001).
  • [ISSN] 1971-4009
  • [Journal-full-title] The neuroradiology journal
  • [ISO-abbreviation] Neuroradiol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Ito T, Tsutsumi T, Ohno K, Takizawa T, Kitamura K: Intracranial angiosarcoma arising from a schwannoma. J Laryngol Otol; 2007 Jan;121(1):68-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiosarcomas rarely arise from schwannomas, but we describe here a case of angiosarcoma that arose from a remnant of a benign vestibular schwannoma that had been removed 10 years earlier.
  • Although we attempted surgical resection, we could not totally remove the tumour.
  • The patient died nine months after diagnosis, primarily as result of an abscess in the cerebellum and base of the skull.
  • The histological diagnosis was confirmed by the immunohistochemical findings of positivity for CD34 antigen and S-100 protein in the resected tumour.A review of the literature revealed four other cases of angiosarcoma with schwannoma, all of which arose from an extracranial nerve.
  • [MeSH-major] Brain Neoplasms / pathology. Hemangiosarcoma / pathology. Neoplasms, Second Primary / pathology. Neurilemmoma / pathology
  • [MeSH-minor] Aged. Brain Abscess / microbiology. Fatal Outcome. Humans. Male. Neoplasm Invasiveness. Staphylococcal Infections / microbiology

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16995966.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 11
  •  go-up   go-down


55. Marshall AE, Martin SE, Agaram NP, Chen JH, Horn EM, Douglas-Akinwande AC, Hattab EM: A 61-year-old woman with osteomalacia and a thoracic spine lesion. Brain Pathol; 2010 Mar;20(2):499-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phosphaturic mesenchymal tumor, mixed connective tissue variant (PMT-MCT) is a rare, largely benign, mesenchymal neoplasm almost invariably associated with oncogenic osteomalacia.
  • [MeSH-major] Osteomalacia / diagnosis. Osteomalacia / pathology. Spinal Neoplasms / diagnosis. Spinal Neoplasms / pathology. Thoracic Vertebrae
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasms, Complex and Mixed / complications. Neoplasms, Complex and Mixed / diagnosis. Neoplasms, Complex and Mixed / pathology. Neoplasms, Connective Tissue / complications. Neoplasms, Connective Tissue / diagnosis. Neoplasms, Connective Tissue / pathology

  • Genetic Alliance. consumer health - Osteomalacia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20438469.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


56. Gabeau-Lacet D, Grant E, Stemmer-Rachamimov A, Yock T, Tarbell NJ: Sellar abnormalities in female first-degree relatives. Clin Neurol Neurosurg; 2008 Feb;110(2):202-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each of these cases was diagnosed and managed differently, illustrating the relative importance of radiographic imaging, tumor markers and histopathologic examination in the diagnosis and treatment of intracranial disease.
  • One daughter was treated presumptively for germinoma based on characteristic radiographic studies and slightly elevated tumor marker.
  • The other daughter's lesion exhibited radiographic characteristics concerning for pituitary macroadenoma but with slightly elevated germ cell tumor marker, raising the suspicion for germinoma.
  • Biopsy of the intrasellar mass revealed only proteinaceous material and normal anterior pituitary, consistent with cyst content without evidence of neoplasm.
  • Without a clear unifying diagnosis it is difficult to posit an underlying pathology or genetic mechanisms in this unusual set of cases.
  • At least two of the patients had benign cysts.
  • The diagnosis of the third patient is unclear as there was no tissue biopsy.
  • However, it is highly improbable that three female first-degree relatives would develop such lesions in the same brain region simply by chance.
  • [MeSH-major] Central Nervous System Cysts / genetics. Central Nervous System Cysts / pathology. Pituitary Neoplasms / genetics. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035480.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


57. Lu C, Ji Y, Shan F, Guo W, Ding J, Ge D: Solitary fibrous tumor of the pleura: an analysis of 13 cases. World J Surg; 2008 Aug;32(8):1663-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pleura: an analysis of 13 cases.
  • BACKGROUND: Solitary fibrous tumor of the pleura is a rare soft-tissue tumor.
  • In search of appropriate diagnosis and treatment methods, we present our experience with 13 patients.
  • Seven tumors were malignant and the other six were benign.
  • Immunohistochemical staining showed nestin was positive in three malignant solitary fibrous tumors of pleura (3/7), which were negative for CD34.
  • Among them, one patient experienced a recurrence and one patient died of brain metastasis.
  • CONCLUSION: Ultrasonography-guided core needle biopsy combined with immunohistochemical analysis might be a safe and rapid method to provide a confirmatory diagnosis before resection.
  • For smaller, pedunculated tumors, video-assisted thoracic surgery could be a powerful and useful approach.
  • We speculate that CD34-negative and nestin-positive might be a malignant marker for solitary fibrous tumor of pleura.
  • [MeSH-major] Neoplasms, Fibrous Tissue / diagnosis. Neoplasms, Fibrous Tissue / surgery. Pleural Neoplasms / diagnosis. Pleural Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Biopsy, Needle / methods. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Radiography, Thoracic. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1998 May;32(5):423-32 [9639117.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):305-9 [12973709.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1808-12 [11156076.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] Eur J Cardiothorac Surg. 1998 Nov;14(5):453-9 [9860200.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):814-20 [7518652.001]
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):489-92 [1755106.001]
  • [Cites] J Comput Assist Tomogr. 2002 Mar-Apr;26(2):174-9 [11884769.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2678-89 [7260861.001]
  • [Cites] Jpn J Clin Oncol. 1998 Feb;28(2):86-91 [9544821.001]
  • [Cites] Cancer Control. 2006 Oct;13(4):264-9 [17075563.001]
  • [Cites] Differentiation. 1997 Feb;61(3):151-9 [9084133.001]
  • [Cites] Chest. 2000 Mar;117(3):897-900 [10713024.001]
  • [Cites] Hum Pathol. 1995 Apr;26(4):428-31 [7535740.001]
  • [Cites] Acta Neuropathol. 2001 Oct;102(4):349-54 [11603810.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • [Cites] Chest. 1997 Nov 5;112(5):1424-8 [9367487.001]
  • [Cites] Chest. 2004 Mar;125(3):1144-7 [15006980.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Dec;12 (6):928-30 [9489884.001]
  • (PMID = 18427887.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


58. Sasikala M, Kumaravel N: A wavelet-based optimal texture feature set for classification of brain tumours. J Med Eng Technol; 2008 May-Jun;32(3):198-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A wavelet-based optimal texture feature set for classification of brain tumours.
  • In this work, the classification of brain tumours in magnetic resonance images is studied by using optimal texture features.
  • These features are used to classify three sets of brain images - normal brain, benign tumour and malignant tumour.
  • Each selected brain region of interest is characterized with both its energy and texture features extracted from the selected high frequency subband.
  • [MeSH-major] Algorithms. Artificial Intelligence. Brain Neoplasms / diagnosis. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Pattern Recognition, Automated / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432467.001).
  • [ISSN] 0309-1902
  • [Journal-full-title] Journal of medical engineering & technology
  • [ISO-abbreviation] J Med Eng Technol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Alexiou GA, Vartholomatos G, Tsiouris S, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Voulgaris S, Fotopoulos AD: Evaluation of meningioma aggressiveness by (99m)Tc-Tetrofosmin SPECT. Clin Neurol Neurosurg; 2008 Jul;110(7):645-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Although meningiomas usually have a benign clinical course, atypical and malignant types of this brain tumor are associated with high recurrence rates and poor outcome; thus, DNA ploidy and S-phase -- as determined by DNA flow cytometry -- are useful indicators of their biological behavior.
  • Brain single-photon emission computed tomography (SPECT) has been suggested as a potentially useful modality for the metabolic assessment of various brain tumors.
  • PATIENTS AND METHODS: Ten consecutive patients (3 males, 7 females, mean age 64.6 years) with a diagnosis of a symptomatic intracranial meningioma, planned to undergo surgery, were studied.
  • Brain SPECT by (99m)Tc-TF was performed within a week prior to surgical excision and flow cytometric analysis was performed in the excised tissue.
  • RESULTS: Benign meningiomas were diagnosed in 8/10 cases, the remaining 2/10 patients had anaplastic lesions.
  • DNA aneuploidy was found in 2 lesions, the remaining tumors were diploid.
  • There was also a positive correlation between tracer uptake and the level of aneuploidy and tumor grade.
  • CONCLUSION: These results imply that (99m)Tc-TF brain SPECT may have the ability to discriminate benign meningiomas from malignant meningiomas pre-operatively, the tracer uptake being a likely indicator of their proliferative activity.
  • [MeSH-major] Meningeal Neoplasms / radionuclide imaging. Meningioma / radionuclide imaging. Organophosphorus Compounds. Organotechnetium Compounds. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Aged. Cell Cycle. Female. Flow Cytometry. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Reproducibility of Results. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18471956.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


60. Zhi L, Bing L, Yang L, Bo-ning L, Quan H: Cystic papillary meningioma with subarachnoid dissemination: a case report and review of the literature. Pathol Res Pract; 2009;205(8):582-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas usually present as benign tumors corresponding to WHO grade I.
  • We report a case of cystic papillary meningioma in a young female occurring in the lateral ventricle with invasion of brain parenchyma and dissemination of subarachnoid space.
  • The tumor exhibits a marked peritumoral cyst, with contrast enhancement on magnetic resonance imaging (MRI) in accordance with type 2 of Zee's classification of cystic meningioma.
  • Histologically, the tumor displays a classical perivascular pseudopapillary pattern with focal necrosis and subarachnoid space dissemination.
  • Tumor cells are diffusely positive for epithelial membrane antigen (EMA) and vimentin, but lack immunoreactivity for cytokeratin (CK) and glial fibrillary acidic protein (GFAP).
  • MIB-1 labeling is high, accounting for 5% of tumor focally.
  • A diagnosis of primary intraventricular cystic papillary meningioma with subarachnoid space dissemination (WHO grade III) was made.
  • In addition, the biological behavior and the clinical outcome of this tumor are also discussed.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Cysts / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Magnetic Resonance Imaging. Mucin-1 / metabolism. Neoplasm Staging. Treatment Outcome. Vimentin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307065.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Vimentin
  •  go-up   go-down


61. Zhou M, Xu G, Bojanowski CM, Song Y, Chen R, Sun X, Wang W, Chan CC: Differential diagnosis of anterior chamber cysts with ultrasound biomicroscopy: ciliary body medulloepithelioma. Acta Ophthalmol Scand; 2006 Feb;84(1):137-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of anterior chamber cysts with ultrasound biomicroscopy: ciliary body medulloepithelioma.
  • CONCLUSION: Intraocular medulloepithelioma is a rare embryonic benign or malignant neoplasm typically diagnosed in the first decade of life as a ciliary body mass.
  • Lack of glial differentiation may predict a better clinical outcome in primary neuroectodermal brain tumours.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ophthalmol. 1999 Mar;83(3):334-8 [10365043.001]
  • [Cites] Ophthalmology. 1996 Dec;103(12):1998-2006 [9003333.001]
  • [Cites] Ann Neurol. 1996 Apr;39(4):481-9 [8619526.001]
  • [Cites] J Ultrasound Med. 2005 Feb;24(2):247-50 [15661960.001]
  • (PMID = 16445454.001).
  • [ISSN] 1395-3907
  • [Journal-full-title] Acta ophthalmologica Scandinavica
  • [ISO-abbreviation] Acta Ophthalmol Scand
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 EY000222-22
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Other-IDs] NLM/ NIHMS54981; NLM/ PMC2441603
  •  go-up   go-down


62. Zhou J, Li NY, Zhou XJ, Zhou HB, Wu B, Jiang SJ, Ma HH, Zhang RS: [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system]. Zhonghua Bing Li Xue Za Zhi; 2010 Mar;39(3):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study clinicopathologic features, diagnosis, treatment and prognosis of von Hippel-Lindau (VHL) syndrome-related and sporadic hemangioblastomas of the central nervous system (CNS-HB).
  • There were 10 patients presenting other lesions related to VHL, including 6 retinal HBs, 4 pancreatic tumors (endocrine tumor and microcystic cystadenoma), 1 clear renal cell carcinoma, 4 renal cysts and 1 endolymphatic sac tumor.
  • One patient developed 5 different tumors related to VHL within a period of 4 years.
  • Histologically, the tumors showed large and vacuolated stromal cells.
  • Some tumors showed atypical nuclei.
  • Involvement of the brain tissue was seen in 32 cases, among which, 21 patients with available follow-up information were learnt to be alive.
  • Tumor cells of HB stained positive for vimentin, EGFR, Inhibin alpha and D2-40, but negative for CD34 and CD68.
  • CONCLUSIONS: VHL syndrome is a multisystem disorder with a poor prognosis and a high rate of missed diagnosis.
  • The syndrome is characterized by development of various benign and malignant tumors.
  • The most common tumor is CNS-HB, which occurs predominantly in the cerebellum.
  • Patients with VHL syndrome tend to present at a younger age than patients with sporadic CNS-HBs, and VHL related HB occurs more predominantly in the brain stem and spinal cord.
  • Prognosis of CNS-HB patients is not correlated with the nuclear atypicality, expression for Ki-67 and involvement of the brain tissue.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Hemangioblastoma / pathology. von Hippel-Lindau Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Child. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / metabolism. Humans. Inhibins / metabolism. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Receptor, Epidermal Growth Factor / metabolism. Retinal Neoplasms / metabolism. Retinal Neoplasms / pathology. Retinal Neoplasms / surgery. Survival Analysis. Vimentin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Von Hippel-Lindau syndrome.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450758.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Vimentin; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


63. Shrieve DC: Basic principles of radiobiology applied to radiotherapy of benign intracranial tumors. Neurosurg Clin N Am; 2006 Apr;17(2):67-78, v
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basic principles of radiobiology applied to radiotherapy of benign intracranial tumors.
  • The use of ionizing radiation in the treatment of benign intracranial tumors may involve one of several types of ionizing radiation given as single-fraction radiosurgery or fractionated radiotherapy.
  • This article discusses the basic radiobiologic principles applicable to radiotherapy of benign brain tumors.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / radiotherapy. Radiobiology / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793500.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Kernick D, Stapley S, Goadsby PJ, Hamilton W: What happens to new-onset headache presented to primary care? A case-cohort study using electronic primary care records. Cephalalgia; 2008 Nov;28(11):1188-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Records of patients who presented with primary headache (migraine, tension-type headache, cluster headache) or undifferentiated headache (no further descriptor) were examined for the subsequent year for subarachnoid haemorrhage, primary brain tumour, benign space-occupying lesion, temporal arteritis, stroke and transient ischaemic attack.
  • The 1-year risk of a malignant brain tumour with new undifferentiated headache was 0.15%, rising to 0.28% above the age of 50 years.
  • The risk for a benign space-occupying lesion was 0.05% for an undifferentiated and 0.009% for a primary headache.
  • Accepting the limitations of this approach, our data can inform management guidelines for new presentations of headache in primary care and confirm the need for follow-up, even if a primary headache diagnosis is made.
  • [MeSH-major] Headache / diagnosis. Headache / epidemiology. Headache / etiology
  • [MeSH-minor] Adult. Brain Diseases / complications. Case-Control Studies. Female. Humans. Male. Middle Aged. Primary Health Care

  • MedlinePlus Health Information. consumer health - Headache.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Headache. 2011 Feb;51(2):346-52 [21284622.001]
  • (PMID = 18771496.001).
  • [ISSN] 1468-2982
  • [Journal-full-title] Cephalalgia : an international journal of headache
  • [ISO-abbreviation] Cephalalgia
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


65. Mainio A, Hakko H, Niemelä A, Koivukangas J, Räsänen P: Gender difference in relation to depression and quality of life among patients with a primary brain tumor. Eur Psychiatry; 2006 Apr;21(3):194-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender difference in relation to depression and quality of life among patients with a primary brain tumor.
  • OBJECTIVE: We studied the relationship between depressive symptoms and quality of life (QOL) as well as functional status in primary brain tumor patients at recurrent measurements.
  • Differences in QOL between depressive and non-depressive samples by gender were controlled for tumor characteristics and patients' psychosocial factors.
  • MATERIALS AND METHODS: The data consisted of 77 patients with a primary brain tumor, 30 males and 47 females.
  • Depression of the patients was assessed by Beck Depression Inventory (BDI) and Crown-Crisp Experiential Index (CCEI), functional status by Karnofsky Performance scale (KPS) and QOL by Sintonen's 15D before tumor operation as well as at 3 months and at 1 year from surgical operation of the tumor.
  • Depressive patients with a benign brain tumor had significantly worse QOL versus non-depressive ones.
  • DISCUSSION AND CONCLUSION: Decreased QOL was strongly related to depression, especially among patients with a benign brain tumor.
  • [MeSH-major] Brain Neoplasms / psychology. Depressive Disorder / psychology. Glioma / psychology. Patients / psychology. Quality of Life / psychology


66. Zhou GF, Wang XY, Huang MP: [BOLD-fMRI in sensory area and motor hand functional area with brain tumor in the central area]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul;33(7):576-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [BOLD-fMRI in sensory area and motor hand functional area with brain tumor in the central area].
  • OBJECTIVE: To explore the geomorphological performance, the characteristics of volume, and the largest signal intension of blood oxygenation level dependent functional magnetic resonance imaging (BOLD-fMRI) in brain tumors located in or closed to the central area.
  • METHODS: We recruited 13 normal volunteers and 31(13 benign tumors and 18 malignant tumors) patients with brain tumor located in or closed to the central area, to examine both side hand motor and tactile function by BOLD-fMRI and obtained the activation map and its superposition image with T1 imaging, the volume, and the largest signal intension of the functional area by SPM software which manipulated the raw data in the off-line work station.
  • There was difference in the activated signal pixel number and the largest signal intension of the functional area between the benign brain tumors, malignant brain tumors, and the normal volunteers (P < 0.05).
  • The shape, anatomic location, the volume, and the largest signal intension of the functional area were changed in the patients with brain tumors.
  • CONCLUSION: BOLD-fMRI is a valid method to assess the pre-surgical risk of patients with brain tumors, which can get the volume, the largest signal intension, the basic shape,and the anatomic location of the functional area.
  • [MeSH-major] Brain Neoplasms / physiopathology. Hand / physiopathology. Magnetic Resonance Imaging / methods. Motor Cortex / physiopathology. Somatosensory Cortex / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18667768.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


67. Kubo O, Chernov M, Izawa M, Hayashi M, Muragaki Y, Maruyama T, Hori T, Takakura K: Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation? Minim Invasive Neurosurg; 2005 Dec;48(6):334-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation?
  • Malignant transformation of benign neoplasm after radiosurgery is usually diagnosed based on the initial presence of benign tumor, its exposure to ionizing radiation, elapsed time from radiation exposure to malignant progression, and different histological characteristics or growth rate of the regrowing tumor comparing with those originally treated.
  • Three presented cases fulfilled these diagnostic criteria; however, it seems that progression of the tumors (schwannoma, meningioma, chordoma) resulted from the natural course of the disease, rather than represented side effects of gamma knife radiosurgery.
  • Evaluation of the proliferative potential of the benign neoplasm before radiosurgical treatment either directly, if tumor sampling is available, or indirectly, by calculation of the tumor growth rate and/or analysis of the data of the metabolic imaging (PET, MRS) is important for identification of "aggressive" subtypes, precise prediction of prognosis, and confirmation of the radiation-induced malignant transformation in cases of tumor regrowth.
  • [MeSH-major] Brain Neoplasms / surgery. Cell Transformation, Neoplastic / radiation effects. Chordoma / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasms, Radiation-Induced / physiopathology. Neurilemmoma / surgery. Radiosurgery / adverse effects
  • [MeSH-minor] Adult. Brain Diseases / surgery. Cell Proliferation. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432782.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


68. Alam E, Wilson RD, Vargo MM: Inpatient cancer rehabilitation: a retrospective comparison of transfer back to acute care between patients with neoplasm and other rehabilitation patients. Arch Phys Med Rehabil; 2008 Jul;89(7):1284-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inpatient cancer rehabilitation: a retrospective comparison of transfer back to acute care between patients with neoplasm and other rehabilitation patients.
  • OBJECTIVE: To determine whether patients with diagnoses of neoplasm undergoing acute rehabilitation differ from other patients in frequency of acute care transfer and type of medical complications.
  • PARTICIPANTS: Patients with diagnosis of neoplasm (n=40) and patients without neoplasm (n=253) requiring transfer were identified from a database of 2801 rehabilitation discharges over nearly a 4-year period.
  • RESULTS: Significant difference occurred in overall rate of transfer between patients with neoplasm (21%) and controls (9.7%; P<.001).
  • When evaluated separately for type of neoplasm (with patients receiving corresponding type of rehabilitation as controls), a significantly higher rate of transfer to acute care was found for brain tumor (25% vs 12%; P=.004) and spinal cord neoplasms (23% vs 10%; P=.009), but statistical significance was not reached for other tumor types (12.5% vs 7.4%; P=.19).
  • Patients with stroke with neoplasm as a comorbidity, analyzed separately, with the other patients with stroke as controls, had significantly higher risk of transfer (22% vs 10%; P=.012).
  • Logistic regression analysis found an odds ratio (OR) of 2.5 for unplanned transfer among patients with diagnosis of neoplasm (OR=2.5 for malignancy; OR=2.4 for benign neoplasm).
  • Patients with neoplasm had infection as the most common reason for transfer (28% of the neoplasm transfers vs 18% of other transfers; P=.01), whereas in the nonneoplasm group, cardiopulmonary factors predominated (12% of patients with tumor vs 31% of patients without tumor transfers; P<.001).
  • CONCLUSIONS: In the present sample, patients with neoplasm were more likely to require transfer than patients without neoplasm, although this pattern did not reach statistical significance for noncentral nervous system cases.
  • Overall, patients with neoplasm appear more likely than those without neoplasm to have an infectious cause for unplanned transfer.
  • [MeSH-major] Critical Care. Neoplasms / epidemiology. Neoplasms / rehabilitation. Patient Transfer
  • [MeSH-minor] Aged. Brain Neoplasms / epidemiology. Brain Neoplasms / rehabilitation. Cohort Studies. Comorbidity. Diabetes Mellitus / epidemiology. Female. Heart Diseases / epidemiology. Hospitalization. Humans. Logistic Models. Male. Middle Aged. Pulmonary Disease, Chronic Obstructive / epidemiology. Retrospective Studies. Spinal Cord Neoplasms / epidemiology. Stroke / epidemiology

  • MedlinePlus Health Information. consumer health - Critical Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586130.001).
  • [ISSN] 1532-821X
  • [Journal-full-title] Archives of physical medicine and rehabilitation
  • [ISO-abbreviation] Arch Phys Med Rehabil
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K12- HD01097
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


69. Tonsgard JH: Clinical manifestations and management of neurofibromatosis type 1. Semin Pediatr Neurol; 2006 Mar;13(1):2-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with variable expression.
  • Neurologic complications include tumors of the peripheral nerves, nerve roots, and plexi; spinal cord compression; dural ectasias; learning disabilities; attention deficit; headaches; seizures; brain tumors; deafness; hydrocephalus; and stroke.
  • High-intensity signals on brain magnetic resonance imaging are a frequent finding without known clinical significance.
  • Most brain tumors are benign and asymptomatic, but malignant brain tumors occur.
  • The major cause of death is malignancy, including brain tumors and malignant peripheral nerve sheath tumors.
  • [MeSH-major] Nervous System Neoplasms / complications. Nervous System Neoplasms / therapy. Neurofibromatosis 1 / complications. Neurofibromatosis 1 / therapy


70. Aihara N, Mase M, Yamada K: [Treatment of benign brain tumor in elderly patients]. Nihon Rinsho; 2005 Sep;63 Suppl 9:600-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of benign brain tumor in elderly patients].
  • [MeSH-major] Adenoma / therapy. Cochlear Nerve / surgery. Cranial Nerve Neoplasms / therapy. Pituitary Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16201588.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Dopamine Agonists; 3A64E3G5ZO / Bromocriptine
  • [Number-of-references] 13
  •  go-up   go-down


71. Balaji R, Ramachandran K: Imaging of desmoplastic infantile ganglioglioma: a spectroscopic viewpoint. Childs Nerv Syst; 2009 Apr;25(4):497-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Desmoplastic infantile gangliogliomas (DIG) are rare benign intracranial neoplasms of early childhood with involvement of superficial cerebral cortex and leptomeninges.
  • The purpose of the study was to determine the alterations in metabolite ratios occurring in the neoplasm and combine with magnetic resonance (MR) imaging features to narrow down the diagnosis.
  • Single-voxel short TE (1)H MR spectroscopy was used to study the changes in metabolite ratios in the tumor.
  • RESULTS: Comparison of metabolite ratios between normal brain tissue and tumor-affected region showed lower N-acetyl aspartate to creatine (Cr; 1.58 vs.1.28), higher choline to Cr (0.82 vs.2.03), and no significant change in myo-inositol to Cr (0.42 vs.0.39).
  • CONCLUSION: MR spectroscopy and imaging provide valuable information in the diagnosis of DIG.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Ganglioglioma / diagnosis. Ganglioglioma / metabolism
  • [MeSH-minor] Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Brain / pathology. Brain / physiopathology. Child. Choline / metabolism. Creatine / metabolism. Diagnosis, Differential. Humans. Inositol / metabolism. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Male

  • Genetic Alliance. consumer health - Desmoplastic Infantile Ganglioglioma.
  • Genetic Alliance. consumer health - Ganglioglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 1994 Jul-Aug;4(4):545-51 [7949679.001]
  • [Cites] Ann N Y Acad Sci. 1997 May 30;820:75-96 [9237450.001]
  • [Cites] Pediatr Radiol. 2005 Oct;35(10):1024-6 [15900435.001]
  • [Cites] Brain. 2006 Feb;129(Pt 2):352-65 [16291806.001]
  • [Cites] Childs Nerv Syst. 2003 Jun;19(5-6):292-7 [12750935.001]
  • [Cites] NMR Biomed. 1991 Apr;4(2):59-63 [1677586.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jul;173(1):119-25 [10397111.001]
  • [Cites] Neurosurg Rev. 1998;21(1):31-5 [9584283.001]
  • [Cites] Childs Nerv Syst. 2006 Aug;22(8):786-809 [16838193.001]
  • [Cites] Pediatr Radiol. 2006 Jun;36(6):541-5 [16552586.001]
  • [Cites] Biochim Biophys Acta. 1987 Apr 20;907(1):33-45 [3032258.001]
  • [Cites] Radiographics. 2001 Nov-Dec;21(6):1533-56 [11706224.001]
  • [Cites] Magn Reson Q. 1994 Dec;10(4):191-247 [7873353.001]
  • [Cites] NMR Biomed. 1992 Sep-Oct;5(5):226-33 [1449961.001]
  • [Cites] Neurosurgery. 1994 Apr;34(4):583-9; discussion 589 [8008154.001]
  • [Cites] Neurosurgery. 1992 Aug;31(2):195-202 [1513425.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):271-5 [16205962.001]
  • [Cites] NMR Biomed. 1992 Sep-Oct;5(5):303-24 [1333263.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Oct;16(9):1821-33 [8693982.001]
  • [Cites] Dev Neurosci. 2005 Jan-Feb;27(1):59-76 [15886485.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1825-32 [9581820.001]
  • [Cites] Acta Neuropathol. 1993;85(2):199-204 [8442411.001]
  • [Cites] J Neurosurg. 1987 Jan;66(1):58-71 [3097276.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Jun-Jul;25(6):1028-33 [15205142.001]
  • (PMID = 19139903.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 30KYC7MIAI / Aspartic Acid; 4L6452S749 / Inositol; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


72. Debling D, Spix C, Blettner M, Michaelis J, Kaatsch P: The cohort of long-term survivors at the German childhood cancer registry. Klin Padiatr; 2008 Nov-Dec;220(6):371-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Since 1980 the GCCR systematically ascertains all malignant neoplasms and benign brain tumours in children under the age of 15 years at diagnosis.
  • Participants are followed up actively by the treating hospitals and the clinical study groups in the first years after diagnosis, and by the GCCR thereafter.
  • Those groups are the GCCR (secondary malignant neoplasms), LESS (late effects after chemotherapy), RiSK (late effects after radiotherapy), and the working group on quality of life (quality of life and data on life circumstances).
  • LTS for patients with leukemia and lymphomas is particularly complete, whereas for patients with brain tumours it is less complete.
  • [MeSH-major] Brain Neoplasms / therapy. Leukemia / therapy. Lymphoma / therapy. Neoplasms / therapy. Registries. Survivors
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Follow-Up Studies. Humans. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / therapy. Young Adult


73. Stavrinou P, Magras I, Stavrinou LC, Zaraboukas T, Polyzoidis KS, Selviaridis P: Primary extracerebral meningeal glioblastoma: clinical and pathological analysis. Cent Eur Neurosurg; 2010 Feb;71(1):46-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary meningeal gliomas are uncommon tumors in the subarachnoid space, their primary characteristic being the absence of any obvious connection to the brain parenchyma.
  • Rarely, they are quite malignant and assume a bulky, well circumscribed appearance rendering the differential diagnosis from other CNS neoplasms difficult.
  • At surgery, the outer layer of the dura mater was intact and there was a clear brain-tumor interface without obvious pial disruption.
  • Histological examination showed a biphasic pattern consisting of benign connective tissue intermingled with bundles of what seemed to be a glioblastoma.
  • The tumor was identified as a primary meningeal glioblastoma.
  • This time, the pathological findings of the tumor were those of a typical glioblastoma multiforme.
  • We discuss the origin of the initial neoplasm and also the differential diagnosis that needs to include meningioma, aggressive glioblastoma infiltrating the dura and a recently recognized bimorphic CNS tumor: the desmoplastic glioblastoma.
  • [MeSH-major] Glioblastoma / pathology. Glioblastoma / surgery. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery
  • [MeSH-minor] Dura Mater / pathology. Glial Fibrillary Acidic Protein / metabolism. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart * New York.
  • (PMID = 20175027.001).
  • [ISSN] 1868-4912
  • [Journal-full-title] Central European neurosurgery
  • [ISO-abbreviation] Cent Eur Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen
  •  go-up   go-down


74. Meningioma. Understanding this usually benign brain tumor. Mayo Clin Health Lett; 2010 Jul;28(7):4-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma. Understanding this usually benign brain tumor.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Health Knowledge, Attitudes, Practice. Meningioma / diagnosis. Meningioma / therapy

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20799379.001).
  • [ISSN] 0741-6245
  • [Journal-full-title] Mayo Clinic health letter (English ed.)
  • [ISO-abbreviation] Mayo Clin Health Lett
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Fukuoka S: [Stereotactic irradiation (Gamma knife) for benign brain tumors]. Nihon Rinsho; 2005 Sep;63 Suppl 9:412-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Stereotactic irradiation (Gamma knife) for benign brain tumors].
  • [MeSH-major] Cochlear Nerve. Cranial Nerve Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Pituitary Neoplasms / surgery. Radiosurgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16201556.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 9
  •  go-up   go-down


76. Walker RA, Wadman MC: Headache in the elderly. Clin Geriatr Med; 2007 May;23(2):291-305, v-vi
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Particular emphasis should be placed on excluding subarachnoid hemorrhage, subdural hematoma, giant cell arteritis, intracranial neoplasm, cerebrovascular accident, acute-angle-closure glaucoma, and infectious etiologies such as meningitis and encephalitis.
  • Once life-threatening disorders are excluded, the geriatrician can focus on more benign etiologies such as migraine, tension headache, and medication withdrawal.
  • This article discusses headaches that require emergent treatment and then describes more benign etiologies of headaches.
  • [MeSH-major] Brain Diseases / complications. Headache / etiology
  • [MeSH-minor] Aged. Carbon Monoxide Poisoning / complications. Carbon Monoxide Poisoning / diagnosis. Glaucoma, Angle-Closure / complications. Glaucoma, Angle-Closure / diagnosis. Headache Disorders, Primary / diagnosis. Humans. Meningitis / complications. Meningitis / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Headache.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462518.001).
  • [ISSN] 0749-0690
  • [Journal-full-title] Clinics in geriatric medicine
  • [ISO-abbreviation] Clin. Geriatr. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


77. Temprano T, Fernández-de León R, Rial JC, Fernández JM, Mateos V: [Cystic bulbar hemangioblastoma]. Rev Neurol; 2008 Aug 1-15;47(3):134-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hemangioblastoma quístico de bulbo raquídeo.
  • INTRODUCTION: Hemangioblastomas are neoplasm of vascular type having benign characteristics.
  • They represent between 2-3% of brain tumors and 7-12% of neoformative processes in the posterior fossa.
  • Brain tumor was diagnosed by neuroimage techniques.
  • The histological study confirmed the hemangioblastoma diagnosis.
  • The bulbar localization is infrequent (which represents less percentage than 5% of cerebral hemangioblastomas) likewise the clinical manifestation though hiccups.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Hemangioblastoma / diagnosis

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18654967.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


78. Niranjan A, Kondziolka D, Lunsford LD: Neoplastic transformation after radiosurgery or radiotherapy: risk and realities. Otolaryngol Clin North Am; 2009 Aug;42(4):717-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In recent years, the use of radiosurgery or radiotherapy for benign brain tumors has increased significantly.
  • Although long-term follow-up from several centers suggests that radiosurgery or radiotherapy is effective and safe, there are particular concerns regarding development of radiation-induced tumors.
  • This article reviews the use of radiosurgery and fractionated radiation therapy with particular regard to new tumor induction and malignant transformation.
  • The authors have found that the risk of radiation associated tumors after radiosurgery or radiotherapy for benign brain tumors is very low.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Cell Transformation, Neoplastic / pathology. Neoplasms, Radiation-Induced / epidemiology. Neoplasms, Radiation-Induced / pathology. Radiosurgery / adverse effects

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19751875.001).
  • [ISSN] 1557-8259
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


79. Georgiadis P, Cavouras D, Kalatzis I, Glotsos D, Athanasiadis E, Kostopoulos S, Sifaki K, Malamas M, Nikiforidis G, Solomou E: Enhancing the discrimination accuracy between metastases, gliomas and meningiomas on brain MRI by volumetric textural features and ensemble pattern recognition methods. Magn Reson Imaging; 2009 Jan;27(1):120-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancing the discrimination accuracy between metastases, gliomas and meningiomas on brain MRI by volumetric textural features and ensemble pattern recognition methods.
  • Three-dimensional (3D) texture analysis of volumetric brain magnetic resonance (MR) images has been identified as an important indicator for discriminating among different brain pathologies.
  • The purpose of this study was to evaluate the efficiency of 3D textural features using a pattern recognition system in the task of discriminating benign, malignant and metastatic brain tissues on T1 postcontrast MR imaging (MRI) series.
  • The dataset consisted of 67 brain MRI series obtained from patients with verified and untreated intracranial tumors.
  • The latter, in conjunction with using 3D textural features, enabled boosting up the performance of the system in discriminating metastatic, malignant and benign brain tumors with 77.14%, 89.19% and 93.33% accuracy, respectively.
  • The proposed system might be used as an assisting tool for brain tumor characterization on volumetric MRI series.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Image Enhancement / methods. Imaging, Three-Dimensional. Magnetic Resonance Imaging / methods. Meningioma / diagnosis. Pattern Recognition, Automated / methods
  • [MeSH-minor] Diagnosis, Differential. Humans. Least-Squares Analysis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602785.001).
  • [ISSN] 0730-725X
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Knisely JP, Linskey ME: Less common indications for stereotactic radiosurgery or fractionated radiotherapy for patients with benign brain tumors. Neurosurg Clin N Am; 2006 Apr;17(2):149-67, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Less common indications for stereotactic radiosurgery or fractionated radiotherapy for patients with benign brain tumors.
  • Microsurgical resection remains the mainstay of treatment for truly benign brain tumors that can be safely resected because of the potential for permanent cure with most histologic findings, including most of the histologic findings discussed in this article.
  • Physicians must keep in mind the indolent nature of many of the benign brain tumors and realize that many patients are likely to live out normal life spans if tumor control is achieved.
  • Therefore, it is not sufficient simply to consider local tumor control rates and short-term toxicity risks when choosing between surgery, stereotactic radiosurgery, and fractionated radiotherapy.
  • For benign brain tumors, these decisions may have consequences that last for decades.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Patient Selection
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / radiotherapy. Astrocytoma / surgery. Chordoma / diagnosis. Chordoma / radiotherapy. Chordoma / surgery. Dose Fractionation. Glomus Tumor / diagnosis. Glomus Tumor / radiotherapy. Glomus Tumor / surgery. Humans. Magnetic Resonance Imaging. Neurocytoma / diagnosis. Neurocytoma / radiotherapy. Neurocytoma / surgery. Paraganglioma / diagnosis. Paraganglioma / radiotherapy. Paraganglioma / surgery. Paraganglioma, Extra-Adrenal / diagnosis. Paraganglioma, Extra-Adrenal / radiotherapy. Paraganglioma, Extra-Adrenal / surgery. Pinealoma / diagnosis. Pinealoma / radiotherapy. Pinealoma / surgery. Radiosurgery / methods. Skull Base Neoplasms / diagnosis. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793507.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


81. Khong SY, Leach J, Greenwood C: Meningioma mimicking puerperal psychosis. Obstet Gynecol; 2007 Feb;109(2 Pt2):515-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Meningiomas are slow-growing benign brain tumors.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Psychotic Disorders / etiology. Puerperal Disorders / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Pregnancy. Pregnancy Trimester, Third

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Postpartum Care.
  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267878.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Hardell L, Carlberg M, Hansson Mild K: Case-control study on cellular and cordless telephones and the risk for acoustic neuroma or meningioma in patients diagnosed 2000-2003. Neuroepidemiology; 2005;25(3):120-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a case-control study on the use of cellular and cordless telephones and the risk for brain tumors.
  • We report the results for benign brain tumors with data from 413 cases (89% response rate), 305 with meningioma, 84 with acoustic neuroma, 24 with other types and 692 controls (84% response rate).
  • [MeSH-major] Cell Phones / utilization. Meningeal Neoplasms / etiology. Meningioma / etiology. Neuroma, Acoustic / etiology

  • Genetic Alliance. consumer health - Acoustic Neuroma.
  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 15956809.001).
  • [ISSN] 0251-5350
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


83. Todaro L, Christiansen S, Varela M, Campodónico P, Pallotta MG, Lastiri J, Sacerdote de Lustig E, Bal de Kier Joffé E, Puricelli L: Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol; 2007 Jun;83(2):135-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors.
  • We studied by Western blot the pattern of serum NCAM bands in patients with gliomas (n = 34), with brain metastasis of different primary cancers (n = 27) and with benign brain tumors (n = 22)] compared with healthy controls (n = 69).
  • A similar pattern was found in patients with brain metastasis or brain benign tumors, suggesting that the pattern of serum NCAM bands would be useful to detect brain tumor pathology.
  • Interestingly, we found that 9/12 patients with glioma showed a significant decrease in NCAM HMW/LMW ratio between 1-3 months after successful tumor removal.
  • Thus, serum NCAM could be a useful marker for monitoring treatment.NCAM expression was also analyzed at tissular level in 59 glioma sections from paraffined tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Glioma / metabolism. Neural Cell Adhesion Molecules / metabolism
  • [MeSH-minor] Adult. Aged. Brain / metabolism. Case-Control Studies. Female. Gene Expression Profiling. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Melanoma / metabolism. Melanoma / secondary. Middle Aged. Protein Isoforms. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. Statistics, Nonparametric. Survival Analysis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1267-76 [9777989.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):106-10 [9662259.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1991 Summer;3(3):330-3 [1821250.001]
  • [Cites] Prostate. 1997 Aug 1;32(3):214-20 [9254901.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Brain Res Mol Brain Res. 1999 Dec 10;74(1-2):69-82 [10640677.001]
  • [Cites] J Neurochem. 1989 Nov;53(5):1372-8 [2795005.001]
  • [Cites] Surgery. 2001 Nov;130(5):834-43 [11685193.001]
  • [Cites] Int J Dev Neurosci. 1993 Oct;11(5):681-90 [8116479.001]
  • [Cites] Int J Cancer. 1994 Jul 1;58(1):116-22 [8014007.001]
  • [Cites] Pancreas. 2001 Mar;22(2):122-5 [11249065.001]
  • [Cites] Int J Colorectal Dis. 2005 Jan;20(1):57-61 [15309466.001]
  • [Cites] Semin Cell Biol. 1992 Jun;3(3):189-97 [1623208.001]
  • [Cites] J Neurosci Res. 1995 May 1;41(1):49-64 [7674377.001]
  • [Cites] J Neurooncol. 2001 Feb;51(3):245-64 [11407596.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):2020-8 [9581848.001]
  • [Cites] Int J Dev Neurosci. 2000 Apr-Jun;18(2-3):193-9 [10715574.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):978-80 [16126882.001]
  • [Cites] Neuropathol Appl Neurobiol. 1991 Jun;17(3):207-17 [1891065.001]
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):283-92 [11839780.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1227-30 [9137477.001]
  • [Cites] Cell. 1988 Dec 23;55(6):955-64 [3203385.001]
  • [Cites] Br J Haematol. 2005 May;129(4):539-41 [15877737.001]
  • [Cites] J Zhejiang Univ Sci B. 2005 Jan;6(1):4-10 [15593384.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6364-70 [2400996.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38305-16 [16172115.001]
  • [Cites] J Neurosci Res. 1999 Jan 1;55(1):99-106 [9890438.001]
  • [Cites] Front Biosci. 2003 May 01;8:d900-11 [12700044.001]
  • [Cites] Prog Neurobiol. 1998 Aug;55(6):659-69 [9670224.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:425-56 [9442880.001]
  • [Cites] Curr Opin Oncol. 2004 Nov;16(6):607-13 [15627025.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):485-94 [16212813.001]
  • [Cites] Neuroimmunomodulation. 1997 Mar-Apr;4(2):57-61 [9483195.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):207-16 [12507300.001]
  • [Cites] Oncology. 2005;69 Suppl 1:14-6 [16210871.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):415-21 [10821486.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):6942-6 [3863135.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):125-8 [12086870.001]
  • [Cites] Neurobiol Dis. 2004 Mar;15(2):387-93 [15006709.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] Glycobiology. 2005 Sep;15(9):887-94 [15872150.001]
  • [Cites] Biol Psychiatry. 1998 May 1;43(9):680-6 [9583002.001]
  • [Cites] Acta Neurol Belg. 2004 Dec;104(4):148-53 [15742604.001]
  • [Cites] Cancer. 1998 May 15;82(10):1921-31 [9587126.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jan;65(1):1-11 [16410743.001]
  • (PMID = 17216340.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neural Cell Adhesion Molecules; 0 / Protein Isoforms
  •  go-up   go-down


84. Takei H, Adesina AM, Powell SZ: Solitary subependymal giant cell astrocytoma incidentally found at autopsy in an elderly woman without tuberous sclerosis complex. Neuropathology; 2009 Apr;29(2):181-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subependymal giant cell astrocytoma (SEGA) is a benign, slowly growing tumor typically occurring in the setting of tuberous sclerosis complex (TSC).
  • Postmortem examination of the brain revealed a single 2.1 x 1.0 x 0.8 cm intraventricular nodule in the lateral ventricle.
  • Histologically, it was composed of interlacing bundles of spindle-shaped tumor cells with thin delicate processes admixed with relatively large pleomorphic cells with abundant glassy eosinophilic cytoplasm, as seen in a SEGA.
  • Immunohistochemically, GFAP, S-100 protein, and neuron specific enolase were positive, and synaptophysin labeled a few tumor cells.
  • Also noted were rare isolated MM cells within the tumor (i.e., tumor-to-tumor metastasis).
  • The histopathological differential diagnosis was limited and included giant cell ependymoma and, much less likely, giant cell glioblastoma and pleomorphic xanthoastrocytoma.
  • Tumor metastasis to an occult SEGA is extremely rare.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Aged. Autopsy. Brain / pathology. Brain / physiopathology. Diagnosis, Differential. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Melanoma / pathology. Melanoma / physiopathology. Melanoma / secondary. Neoplasm Metastasis. Phosphopyruvate Hydratase / metabolism. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18673443.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / S100 Proteins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


85. Mentzel HJ, Seidel J, Fitzek C, Eichhorn A, Vogt S, Reichenbach JR, Zintl F, Kaiser WA: Pediatric brain MRI in neurofibromatosis type I. Eur Radiol; 2005 Apr;15(4):814-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric brain MRI in neurofibromatosis type I.
  • In addition to multiple peripheral neurofibromas, NF I predisposed to CNS tumors including optic glioma, astrocytoma and plexiform neurofibroma.
  • The purpose of this pictorial review is to illustrate characteristic brain MR imaging lesions in children with NF I and to give some recommendations about diagnostic imaging procedures in children suffering from NF I.
  • Typical findings in brain MRI are hyperintense lesion on T2-weighted images, so-called unknown bright objects, which may be useful as an additional imaging criterion for NF I.
  • Contrast administration is necessary in MR studies to maximize tumor detection and characterization, to add confidence to the diagnosis of benign probable myelin vacuolization, and to document stability of neoplasm on follow-up examinations.
  • The frequency of follow-up in children with known brain tumors will vary with the tumor grade, biological activity and treatment.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Magnetic Resonance Imaging. Neurofibromatosis 1 / pathology


86. Monaco E 3rd, Kondziolka D, Mongia S, Niranjan A, Flickinger JC, Lunsford LD: Management of brain metastases from ovarian and endometrial carcinoma with stereotactic radiosurgery. Cancer; 2008 Nov 1;113(9):2610-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of brain metastases from ovarian and endometrial carcinoma with stereotactic radiosurgery.
  • BACKGROUND: Metastases to the brain from ovarian and endometrial carcinoma are uncommon and to the authors' knowledge consensus regarding optimal management is lacking.
  • Stereotactic radiosurgery (SRS) has proven useful for the treatment of many benign and malignant brain tumors.
  • METHODS: Twenty-seven patients with brain metastases underwent gamma-knife SRS.
  • Eighteen patients also received whole-brain radiotherapy.
  • A total of 68 tumors were treated with gamma-knife SRS.
  • The median survival was 7 months after the initial diagnosis of brain metastasis and 5 months after SRS.
  • The 1-year survival rate after radiosurgery was 15% and that from the diagnosis of brain metastases was 22%.
  • On final imaging, all tumors were controlled without further growth.
  • CONCLUSIONS: SRS is an acceptable choice for the treatment of brain metastases resulting from ovarian and endometrial carcinoma, and provides local tumor control with limited morbidity.
  • [MeSH-major] Brain Neoplasms / surgery. Cranial Irradiation. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. Radiosurgery
  • [MeSH-minor] Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18780313.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Wadasadawala T, Trivedi S, Gupta T, Epari S, Jalali R: The diagnostic dilemma of primary central nervous system melanoma. J Clin Neurosci; 2010 Aug;17(8):1014-1017
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanomas are malignant neoplasms of melanocytes developing predominantly in the skin, but occasionally arising from eyes, mucous membranes, and the central nervous system (CNS).
  • The CNS can be affected by a spectrum of melanocytic lesions ranging from diffuse neurocutaneous melanosis, to a focal and benign neoplasm (melanocytoma), and to an overtly malignant tumor (melanoma).
  • Primary CNS melanoma cannot be reliably distinguished from metastatic melanoma on neuroimaging and histopathological characteristics alone: its diagnosis is established only after exclusion of secondary metastatic disease from a cutaneous, mucosal or retinal primary.
  • [MeSH-major] Brain Neoplasms / pathology. Cerebellopontine Angle / pathology. Melanoma / pathology. Parietal Lobe / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20627582.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


88. Arai A, Sasayama T, Tamaki M, Sakagami Y, Enoki E, Ohbayashi C, Kohmura E: Rosette-forming glioneuronal tumor of the fourth ventricle--case report. Neurol Med Chir (Tokyo); 2010;50(3):224-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rosette-forming glioneuronal tumor of the fourth ventricle--case report.
  • Rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle is a rare tumor included as a novel glioneuronal neoplasm in the 2007 World Health Organization classification of brain tumors.
  • The tumor was gross totally resected.
  • RGNT of the fourth ventricle should be considered in the differential diagnosis of infratentorial lesions in young adults.
  • The prognosis is benign, but relatively aggressive behaviors such as tumor growth, recurrence, and acute deterioration due to intratumoral hemorrhaging can occur.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Fourth Ventricle / pathology. Infratentorial Neoplasms / pathology. Neoplasms, Neuroepithelial / pathology. Teratoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339273.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


89. Hörmann M: [Neuroblastoma in children]. Radiologe; 2008 Oct;48(10):940-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroblastomas have a very heterogenic clinical presentation, ranging from relatively benign forms with the potential of spontaneous regression, to foudroyant malignant forms.
  • Over half of neuroblastomas must be classified as high-risk tumors with a markedly high rate of recurrence.
  • Despite multidisciplinary therapeutic approaches, the survival rate of children with this type of tumor is still below 40%.
  • An ever-growing amount of data from international studies dating from the early 1970s onwards, points to the necessity of re-evaluating the medical approach in establishing the diagnosis and staging, understanding tumor biology and pathology, as well as therapy planning.
  • [MeSH-major] Bone Marrow Neoplasms / diagnosis. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging. Neuroblastoma / diagnosis. Spinal Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Humans. Infant. Infant, Newborn. Life Expectancy. Mass Screening. Neoplasm Staging. Paraneoplastic Syndromes / diagnosis. Positron-Emission Tomography. Prognosis. Quality of Life. Risk Factors. Ultrasonography


90. Tsuboi Y, Kurimoto M, Nagai S, Kamiyama H, Endo S: Malignant transformation of oligoastrocytoma: a case report. Brain Tumor Pathol; 2007;24(2):63-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of oligoastrocytoma resembling dysembryoplastic neuroepithelial tumor (DNT) with malignant transformation.
  • Magnetic resonance imaging (MRI) revealed an extensive left temporal lobe tumor.
  • She underwent partial resection of the tumor under awake surgery, while preserving her language function.
  • The surgical specimen showed that the majority of the tumor was composed of a glioneuronal element.
  • Therefore, our first pathological diagnosis was oligoastrocytoma and DNT.
  • The tumor recurred at the left temporal lobe in June 2005.
  • The pathological diagnosis was anaplastic oligoastrocytoma with a MIB-1 staining index of 79%.
  • She received PAV (procarvazine, ACNU, and vincristine) chemotherapy, and the tumor subsided transiently.
  • The authors concluded that this tumor could be a malignant transformation of oligoastrocytoma mimicking DNT, and we wish to give warning that the presence of a glioneuronal component is not an absolute benign hallmark.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology. Neuroectodermal Tumors, Primitive / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Transformation, Neoplastic. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Neurosurgical Procedures. Radiotherapy

  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095133.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


91. Widdel L, Kleinschmidt-DeMasters BK, Kindt G: Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema. World Neurosurg; 2010 Jul;74(1):165-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema.
  • BACKGROUND: Tumor-to-tumor metastasis is a rare, but well-reported, curiosity in which one type of primary neoplasm metastasizes to another primary tumor type within the same person.
  • OBJECTIVE: To report two examples of benign meningiomas in which metastatic tumor deposits from the patient's hematopoietic neoplasm to the meningioma caused significant peritumoral edema, necessitating semiemergent surgical resection.
  • RESULTS: One patient had multiple myeloma associated with extensive necrosis within his otherwise benign convexity meningioma; first diagnosis of his IgG, kappa-restricted plasma cell dyscrasia was made from this tumor-to-tumor meningioma specimen.
  • The second patient carried a diagnosis of marginal zone lymphoma but then presented 5 years later with symptoms referable to a large dural-based mass with significant surrounding edema, prompting surgical removal.
  • Dural marginal zone lymphoma was identified within epidural, intradural, and subdural spaces, in the same location as an underlying benign meningioma.
  • CONCLUSIONS: Although rare, neurosurgeons should be aware of the entity of tumor-to-tumor metastasis as, in large series, meningiomas are the third most frequent recipient tumor type and pituitary adenomas, the fifth most frequent, probably reflecting their rich vascularity.
  • In examples where the donor tumor type is a hematopoietic neoplasm, significant edema can be produced by the tumor-to-tumor metastasis.
  • [MeSH-major] Brain Edema / etiology. Image Processing, Computer-Assisted. Lymphoma, B-Cell, Marginal Zone / diagnosis. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Meningioma / diagnosis. Multiple Myeloma / diagnosis. Multiple Myeloma / secondary. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Brain / pathology. Brain / surgery. Diagnosis, Differential. Female. Humans. Male. Meninges / pathology. Meninges / surgery. Middle Aged

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21300009.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Cozzi L, Clivio A, Vanetti E, Nicolini G, Fogliata A: Comparative planning study for proton radiotherapy of benign brain tumors. Strahlenther Onkol; 2006 Jul;182(7):376-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative planning study for proton radiotherapy of benign brain tumors.
  • Twelve cases of "benign" brain tumors were considered (meningiomas, neurinomas, and hypophyseal adenomas).
  • Organs at risk included chiasm, brainstem, eyes and optic nerves as well as the not otherwise specified healthy brain tissue in view of long-term toxicity.
  • Plans designed with the spot-scanning technique presented the minimum involvement of healthy tissue (e. g., the lowest maximum significant dose to healthy brain [25.6 Gy] or the lowest conformity index [CI(95) = 1.3], between 38% and 46% lower than for the other techniques).
  • [MeSH-major] Brain Neoplasms / radiotherapy. Protons / therapeutic use. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826355.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


93. Agaoglu FY, Ayan I, Dizdar Y, Kebudi R, Gorgun O, Darendeliler E: Ependymal tumors in childhood. Pediatr Blood Cancer; 2005 Sep;45(3):298-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymal tumors in childhood.
  • BACKGROUND: Ependymal tumors are classified as ependymoma (benign or low grade) versus anaplastic ependymoma (malignant or high grade).
  • Ependymomas represent 5-10% of intracranial neoplasm in children.
  • In this study, demographic data and the treatment results of pediatric patients with ependymal tumors, treated in a single institute, is reported.
  • PATIENTS AND METHODS: Between 1989 and 2001, 40 (22 M/18 F) previously untreated patients with a median age of 5.5 years (3 months-15 years), of histologically proven ependymal tumors (except ependymoblastomas) were referred to the Institute of Oncology, University of Istanbul.
  • Total tumor resection was performed in 20 patients (50%), subtotal in 18 patients (45%), and biopsy only in 2 patients (5%).
  • CONCLUSIONS: The majority of complete responders were patients who had total tumor removal.
  • The median age at diagnosis is 6 years in our patient group; younger children (less than 3 years old) have less favorable outcome.
  • [MeSH-major] Brain Neoplasms. Ependymoma

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15770637.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Burghaus S, Hölsken A, Buchfelder M, Fahlbusch R, Riederer BM, Hans V, Blümcke I, Buslei R: A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas. Virchows Arch; 2010 Mar;456(3):287-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas.
  • Craniopharyngiomas (CP) are benign epithelial tumors of the sellar region and can be clinicopathologically distinguished into adamantinomatous (adaCP) and papillary (papCP) variants.
  • Both subtypes are classified according to the World Health Organization grade I, but their irregular digitate brain infiltration makes any complete surgical resection difficult to obtain.
  • Herein, we characterized the cellular interface between the tumor and the surrounding brain tissue in 48 CP (41 adaCP and seven papCP) compared to non-neuroepithelial tumors, i.e., 12 cavernous hemangiomas, 10 meningiomas, and 14 metastases using antibodies directed against glial fibrillary acid protein (GFAP), vimentin, nestin, microtubule-associated protein 2 (MAP2) splice variants, and tenascin-C.
  • Furthermore, the outer tumor cell layer of adaCP showed a distinct expression of MAP2, a novel finding helpful in the differential diagnosis of epithelial tumors in the sellar region.
  • Our data support the hypothesis that adaCP, unlike other non-neuroepithelial tumors of the central nervous system, create a tumor-specific cellular environment at the tumor-brain junction.
  • Whether this facilitates the characteristic infiltrative growth pattern or is the consequence of an activated Wnt signaling pathway, detectable in 90% of these tumors, will need further consideration.
  • [MeSH-major] Craniopharyngioma / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Brain / metabolism. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / metabolism. Humans. Intermediate Filament Proteins / metabolism. Male. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Nerve Tissue Proteins / metabolism. Nestin. Tenascin / metabolism. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1595-603 [17122517.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Dec;28(6):480-8 [12445164.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • [Cites] J Pathol. 2004 Jul;203(3):814-21 [15221941.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 May;7(5):675-87 [17492931.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):778-84 [11533656.001]
  • [Cites] Brain Res. 2002 Jul 12;943(2):174-80 [12101039.001]
  • [Cites] Acta Neurochir (Wien). 2008 Dec;150(12):1213-26 [19002375.001]
  • [Cites] Oncogene. 2005 Dec 8;24(55):8200-4 [16091738.001]
  • [Cites] Glia. 2000 Feb 1;29(3):233-45 [10642750.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3897-904 [8033113.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):89-96 [15146346.001]
  • [Cites] Acta Neuropathol. 2005 Jun;109(6):589-97 [15891929.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Nov 15;139(1):9-17 [12414089.001]
  • [Cites] J Neurochem. 1999 Dec;73(6):2531-7 [10582615.001]
  • [Cites] Glia. 1997 Jan;19(1):35-46 [8989566.001]
  • [Cites] J Biol Chem. 1990 Nov 15;265(32):19679-84 [2174050.001]
  • [Cites] Neurosurgery. 2005 Apr;56(4):763-76 [15792515.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Feb 21;65(2):259-67 [1373996.001]
  • [Cites] Acta Neuropathol. 1978 Sep 15;43(3):191-203 [696237.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):357-64 [18540944.001]
  • [Cites] Pediatr Neurosurg. 1996 Nov;25(5):240-6; discussion 247 [9309787.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Jul 24;68(1):111-23 [1521317.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10894-8 [7479905.001]
  • [Cites] J Cell Sci. 1994 Nov;107 ( Pt 11):3115-25 [7699010.001]
  • [Cites] Cell Tissue Res. 2003 Dec;314(3):315-24 [14523640.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1 Suppl):3-12 [17233305.001]
  • [Cites] Matrix Biol. 2001 Feb;20(1):13-22 [11246000.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):155-70 [3292716.001]
  • [Cites] Eur J Endocrinol. 2005 Apr;152(4):557-67 [15817911.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):12-7 [2352012.001]
  • [Cites] Horm Res. 2008;69(4):193-202 [18204266.001]
  • [Cites] Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):85-92 [15723616.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409 [15807869.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):984-93 [11589429.001]
  • [Cites] Annu Rev Cell Biol. 1989;5:71-92 [2480799.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):471-9 [17630614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(17):6006-9 [3898077.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11771-80 [17178873.001]
  • [Cites] Glia. 1995 Apr;13(4):233-54 [7615335.001]
  • [Cites] Dev Dyn. 2004 May;230(1):1-11 [15108304.001]
  • [Cites] Brain Tumor Pathol. 2005;22(2):75-8 [18095108.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] Eur J Neurosci. 2005 Oct;22(8):1863-72 [16262626.001]
  • [Cites] Pituitary. 2005;8(2):75-9 [16195780.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] Acta Neuropathol. 2007 May;113(5):585-90 [17221204.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Mar 31;134(1-2):87-92 [11947939.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Exp Neurol. 1999 Dec;160(2):348-60 [10619552.001]
  • [Cites] Eur J Endocrinol. 2008 Dec;159 Suppl 1:S95-9 [18775978.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:453-4 [16700324.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2430-9 [14635078.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):206-14 [7616262.001]
  • [Cites] Neuropathology. 2007 Feb;27(1):1-9 [17319278.001]
  • (PMID = 20069432.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Microtubule-Associated Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Tenascin; 0 / Vimentin
  •  go-up   go-down


95. McDonald A: Living with a benign brain tumour. BMJ; 2009;339:b2886
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living with a benign brain tumour.
  • [MeSH-major] Brain Neoplasms / psychology. Glioma, Subependymal / psychology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638372.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM: Epidemiology of intracranial meningioma. Neurosurgery; 2005 Dec;57(6):1088-95; discussion 1088-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are the most frequently reported primary intracranial neoplasms, accounting for approximately 25% of all such lesions diagnosed in the United States.
  • Few studies have examined the risk factors associated with a diagnosis of meningioma with two categories of exposure, hormones (both endogenous and exogenous) and radiation, most strongly associated with meningioma risk.
  • Recent legislation passed in the United States (The Benign Brain Tumor Cancer Registries Amendment Act [H.R.
  • 5204]) mandates registration of benign brain tumors such as meningioma.
  • The increased emphasis on research dedicated to the study of brain tumors coupled with the advent of new tools in genetic and molecular epidemiology make the current era an ideal time to advance knowledge for intracranial meningioma.

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331155.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA089017; United States / NCI NIH HHS / CA / 5R25-CA089017-03; United States / NCI NIH HHS / CA / P50-CA097257; United States / NCI NIH HHS / CA / R01-CA52689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 76
  •  go-up   go-down


97. Soudack M, Guralnik L, Ben-Nun A, Berkowitz D, Postovsky S, Vlodavsky E, Engel A: Imaging features of posterior mediastinal chordoma in a child. Pediatr Radiol; 2007 May;37(5):492-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Evaluation by CT revealed a low-density posterior mediastinal mass initially diagnosed as benign tumor.
  • We present our suggestions for preoperative evaluation of posterior mediastinal tumors.
  • [MeSH-major] Chordoma / diagnosis. Mediastinal Neoplasms / diagnosis. Mediastinum / diagnostic imaging. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Child, Preschool. Cough / etiology. Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Respiratory Sounds. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):743-6 [12972813.001]
  • [Cites] J Pediatr Surg. 1992 Dec;27(12 ):1515-8 [1469556.001]
  • [Cites] AJR Am J Roentgenol. 1996 Jan;166(1):26-7 [8571897.001]
  • [Cites] J Thorac Cardiovasc Surg. 1972 Jun;63(6):922-4 [5028681.001]
  • [Cites] Cancer. 1967 Nov;20(11):1841-50 [6061621.001]
  • [Cites] Hum Pathol. 1995 Dec;26(12):1354-62 [8522309.001]
  • [Cites] Spine (Phila Pa 1976). 1983 Oct;8(7):781-6 [6665580.001]
  • [Cites] Skeletal Radiol. 1980;5(3):171-3 [7209569.001]
  • [Cites] J Pediatr Surg. 2002 Jan;37(1):50-6 [11781986.001]
  • [Cites] Childs Brain. 1981;8(3):198-206 [7238137.001]
  • [Cites] Skeletal Radiol. 2003 Jun;32(6):343-50 [12719927.001]
  • [Cites] Neurol Med Chir (Tokyo). 2002 Apr;42(4):175-80 [12013671.001]
  • [Cites] Arch Pathol Lab Med. 1993 Sep;117(9):927-33 [8368907.001]
  • [Cites] J Fr Med Chir Thorac. 1961 Aug-Sep;15:623-31 [13873536.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Feb;23 (2):248-50 [12559357.001]
  • (PMID = 17345078.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


98. Lönnrot K, Terho M, Kähärä V, Haapasalo H, Helén P: Desmoplastic infantile ganglioglioma: novel aspects in clinical presentation and genetics. Surg Neurol; 2007 Sep;68(3):304-8; discussion 308
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Desmoplastic infantile ganglioglioma is a rare tumor occurring mainly in infants and young children.
  • Both radiological and histopathological appearances may resemble malignancy, although its clinical course is mainly benign.
  • METHODS: Altogether, 5 cases of DIG have been operated on in our hospital since the first diagnosis of DIG in Finland in 1993.
  • In 4 cases, there was a histopathologically verified single cystic tumor.
  • There were no recurrences in any of the patients after tumor resection.
  • For the first time, we describe EGFR and MYCN amplifications in tumors which are, respectively, of their mixed glial and neuronal origin.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / etiology. Ganglioglioma / diagnosis. Ganglioglioma / etiology
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. Epilepsy / etiology. Follow-Up Studies. Humans. Male. Neoplasm Proteins / metabolism. Nerve Tissue Proteins / metabolism. Oncogenes / physiology. Retrospective Studies. Treatment Outcome


99. Sundgren PC, Cao Y: Brain irradiation: effects on normal brain parenchyma and radiation injury. Neuroimaging Clin N Am; 2009 Nov;19(4):657-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain irradiation: effects on normal brain parenchyma and radiation injury.
  • Radiation therapy is a major treatment modality for malignant and benign brain tumors.
  • Concerns of radiation effects on the brain tissue and neurocognitive function and quality of life increase as survival of patients treated for brain tumors improves.
  • In this article, the clinical and neurobehavioral symptoms and signs of radiation-induced brain injury, possible histopathology, and the potential of functional, metabolic, and molecular imaging as a biomarker for assessment and prediction of neurotoxicity after brain irradiation and imaging findings in radiation necrosis are discussed.
  • [MeSH-major] Brain / radiation effects. Brain Injuries / diagnosis. Brain Injuries / etiology. Diagnostic Imaging / methods. Radiation Injuries / diagnosis. Radiation Injuries / etiology. Radiotherapy, Conformal / adverse effects

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19959011.001).
  • [ISSN] 1557-9867
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS064973
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS167505; NLM/ PMC5000393
  •  go-up   go-down


100. Yu AH, Chen L, Li YJ, Zhang GJ, Li KC, Wang YP: Dysembryoplastic neuroepithelial tumors: magnetic resonance imaging and magnetic resonance spectroscopy evaluation. Chin Med J (Engl); 2009 Oct 20;122(20):2433-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysembryoplastic neuroepithelial tumors: magnetic resonance imaging and magnetic resonance spectroscopy evaluation.
  • BACKGROUND: Dysembryoplastic neuroepithelial tumor (DNT) is a rare benign neoplasm of the central nervous system affecting young people.
  • A correct preoperative diagnosis is helpful for planning surgical strategies and improving prognosis.
  • The purpose of this study was to characterize DNTs using magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) and to analyze the value of these two techniques in the diagnosis of DNTs.
  • Tumors were confirmed by surgery.
  • RESULTS: All tumors were supratentorial.
  • The cortex was the main area involved, with nine tumors located in the temporal lobe, three in the frontal lobe, and one on the boundary between the temporal and occipital lobes.
  • Eight tumors had well-demarcated borders.
  • The combination of MRI and MRS techniques were helpful in making a correct presurgical diagnosis.
  • [MeSH-major] Brain Neoplasms / pathology. Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Neoplasms, Neuroepithelial / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079155.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement